data_2e4h_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2e4h _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 7.2 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.909 0.385 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . 0.408 ' NH1' ' HB2' ' A' ' 217' ' ' ARG . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.527 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.423 ' CE1' HG12 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.436 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.414 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.413 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . 0.414 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.423 HG12 ' CE1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 3.6 mm-40 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.538 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.538 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.45 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.527 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 12.9 tt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.476 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 120.474 0.178 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 51.9 mt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.97 0.414 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.525 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.41 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.402 HG22 ' CG ' ' A' ' 241' ' ' TRP . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.401 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.421 ' CZ3' ' HD3' ' A' ' 274' ' ' PRO . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.443 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.525 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 8.7 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.438 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.764 0.316 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.514 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.434 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.417 HG21 ' CG ' ' A' ' 241' ' ' TRP . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.44 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.417 ' CG ' HG21 ' A' ' 234' ' ' THR . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.436 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.44 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.524 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.524 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.423 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.514 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 2.2 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.476 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 . . . . . 0 CA--C 1.523 -0.075 0 CA-C-O 120.387 0.137 . . . . 0.0 111.146 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 5.2 mt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.879 0.371 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . 0.403 ' CG ' ' CG2' ' A' ' 281' ' ' ILE . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.51 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.419 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.439 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.428 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.439 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.417 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.417 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.519 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.519 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.412 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.51 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . 0.403 ' CG2' ' CG ' ' A' ' 217' ' ' ARG . 6.3 tt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 31.6 mm . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.795 0.331 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.515 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.424 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.402 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.44 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.402 ' CG ' HG23 ' A' ' 234' ' ' THR . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.438 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.44 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.5 p-80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.515 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 18.8 tt . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.458 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.521 -0.138 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.434 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 50.7 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.891 0.377 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.503 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.466 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.416 ' CE1' HG12 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.416 HG12 ' CE1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.42 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.42 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.502 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.502 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.457 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.503 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 10.9 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.457 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 3.2 mm-40 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.82 0.343 . . . . 0.0 110.977 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.41 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.427 ' CE1' HG13 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.415 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.415 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.444 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.412 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.427 HG13 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.407 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.504 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.504 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.418 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.449 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 120.497 0.189 . . . . 0.0 111.027 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.731 0.301 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.523 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.423 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.419 ' CZ3' ' O ' ' B' ' 449' ' ' GLU . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.444 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . 0.405 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.514 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.514 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.423 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.523 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 18.8 tt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.486 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER . . . . . 0 C--O 1.227 -0.104 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.868 0.366 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.532 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.427 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.414 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.414 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.438 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.412 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . 0.411 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.427 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.41 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.526 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.526 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.532 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 16.4 tt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.45 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.435 0.16 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.788 0.328 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.538 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.408 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.404 HG22 ' CG ' ' A' ' 241' ' ' TRP . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.447 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.419 ' HB2' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.419 ' CZ2' ' HB2' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.447 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.415 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.543 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.538 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 5.1 tt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.441 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.449 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.787 0.327 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . 0.402 ' HD3' ' CG2' ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.526 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.483 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . 0.402 ' CG2' ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.416 HG23 ' CG ' ' A' ' 241' ' ' TRP . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.431 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.424 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.424 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.445 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.431 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.421 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.421 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.521 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.521 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.526 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 16.3 tt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 . . . . . 0 CA--C 1.521 -0.157 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 31.5 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.761 0.315 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.531 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.469 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.411 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.457 ' CD1' HG12 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.404 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.431 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . 0.412 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.457 HG12 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.414 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.447 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.447 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.531 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 6.5 tt . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.483 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 214' ' ' ILE . 62.1 mt . . . . . 0 N--CA 1.456 -0.148 0 CA-C-O 120.816 0.341 . . . . 0.0 110.988 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.499 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.419 HG21 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.432 ' CE1' HG13 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.434 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.434 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.411 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.402 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.41 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.432 HG13 ' CE1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.404 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.454 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.454 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.418 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.499 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 2.1 tt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.427 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 . . . . . 0 CA--C 1.521 -0.137 0 CA-C-O 120.387 0.137 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 214' ' ' ILE . 48.6 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.864 0.364 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.522 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.418 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.432 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.415 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.429 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.432 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.429 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.518 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.518 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.413 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.522 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 3.6 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.473 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 . . . . . 0 CA--C 1.522 -0.112 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . 0.403 HD11 HG23 ' A' ' 214' ' ' ILE . 61.2 mt . . . . . 0 CA--C 1.528 0.122 0 CA-C-O 120.78 0.324 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.513 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.418 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.415 ' CD1' HG13 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.415 ' HB1' ' CE1' ' A' ' 236' ' ' PHE . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.415 HG13 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.525 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.525 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.463 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.513 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.463 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.4 mt-10 . . . . . 0 N--CA 1.46 0.072 0 CA-C-O 120.451 0.167 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 44.4 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.898 0.38 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.517 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.413 HG22 ' CG ' ' A' ' 241' ' ' TRP . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.43 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.421 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.421 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.421 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.426 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . 0.4 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.43 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.406 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.521 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.521 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.517 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 20.1 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.485 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 . . . . . 0 CA--C 1.521 -0.155 0 CA-C-O 120.372 0.13 . . . . 0.0 111.041 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.853 0.359 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . 0.4 ' CG ' ' CG2' ' A' ' 281' ' ' ILE . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.509 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.402 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.403 ' HB2' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.403 ' CZ2' ' HB2' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . 0.4 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.496 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.496 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.509 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . 0.4 ' CG2' ' CG ' ' A' ' 217' ' ' ARG . 11.5 tt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.444 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . 0.445 HD11 HG21 ' A' ' 214' ' ' ILE . 38.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.92 0.391 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.505 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.425 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . 0.427 ' HB3' ' CE2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.427 ' CE2' ' HB3' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.422 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.425 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.412 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.422 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.497 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.497 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.446 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.505 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 11.8 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.46 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 . . . . . 0 CA--C 1.522 -0.124 0 CA-C-O 120.58 0.229 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.443 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 5.5 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.816 0.341 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.519 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.418 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' THR . . . . . 0.415 HG22 ' CG ' ' A' ' 241' ' ' TRP . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.435 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . 0.415 ' CG ' HG22 ' A' ' 234' ' ' THR . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.435 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 7.6 tp60 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.509 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.509 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.47 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.519 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.6 mt-10 . . . . . 0 CA--C 1.521 -0.136 0 CA-C-O 120.425 0.155 . . . . 0.0 111.038 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 4.1 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.789 0.328 . . . . 0.0 110.891 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 218' ' ' VAL . . . . . 0.536 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 219' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.422 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' PHE . . . . . 0.446 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 248' ' ' GLU . . . . . 0.404 ' CB ' ' CD2' ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . 0.403 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' LEU . . . . . 0.404 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.446 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' PRO . . . . . 0.492 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' HIS . . . . . 0.492 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' VAL . . . . . 0.536 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 449' ' ' GLU . . . . . 0.455 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 0.8 OUTLIER . . . . . 0 CA--C 1.523 -0.094 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 450' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.3 mtt85 . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -71.17 -169.08 0.35 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.904 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 78.7 mt -104.36 150.77 24.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.904 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.24 144.82 50.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 7.2 mt -58.8 139.67 18.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.92 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . 0.408 ' NH1' ' HB2' ' A' ' 217' ' ' ARG . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.527 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.423 ' CE1' HG12 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.436 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.414 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.413 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . 0.414 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.423 HG12 ' CE1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 3.6 mm-40 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.538 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.538 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.45 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.527 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 12.9 tt -80.91 -30.07 11.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.69 80.42 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.463 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 C--N 1.328 -0.369 0 CA-C-O 120.703 0.287 . . . . 0.0 110.862 -179.906 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -99.52 35.87 1.88 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.862 0.363 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 63.52 140.42 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 34.2 mm-40 -140.99 162.65 34.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.82 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.39 17.9 44.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.668 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.476 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 -106.12 25.34 11.11 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 122.894 -0.18 . . . . 0.0 110.96 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.751 0.31 . . . . 0.0 110.918 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -59.44 -77.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 78.2 mt -114.49 146.3 40.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -132.38 148.15 52.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.696 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 51.9 mt -60.06 135.45 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.525 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.41 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.402 HG22 ' CG ' ' A' ' 241' ' ' TRP . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.401 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.421 ' CZ3' ' HD3' ' A' ' 274' ' ' PRO . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.443 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.525 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 8.7 tt -72.58 -23.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -130.29 53.89 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.4 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 5.5 t80 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.64 0.257 . . . . 0.0 110.843 -179.889 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -155.09 -48.39 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.796 0.331 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 -133.58 31.82 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.809 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -113.88 162.73 16.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.864 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.14 16.41 50.65 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.639 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.438 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 -106.18 29.49 6.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.79 0.328 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -78.54 155.32 29.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 36.3 mt -121.94 151.73 40.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.793 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.03 141.59 42.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.945 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt -63.28 142.69 16.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.141 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.514 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.434 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.417 HG21 ' CG ' ' A' ' 241' ' ' TRP . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.44 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.417 ' CG ' HG21 ' A' ' 234' ' ' THR . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.436 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.44 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.524 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.524 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.423 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.514 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 2.2 tt -68.75 -25.56 30.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -58.55 -165.99 0.12 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.481 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 10.6 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.604 0.24 . . . . 0.0 110.865 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.37 73.57 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.912 0.386 . . . . 0.0 110.889 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -99.33 83.66 2.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -139.53 162.46 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.83 -8.17 61.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.823 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.476 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 -94.04 20.75 7.49 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 122.855 -0.203 . . . . 0.0 111.146 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.869 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -136.16 169.35 17.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 76.2 mt -114.61 157.91 22.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.47 145.35 45.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 5.2 mt -58.17 137.63 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.059 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . 0.403 ' CG ' ' CG2' ' A' ' 281' ' ' ILE . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.51 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.419 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.439 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.428 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.439 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.417 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.417 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.519 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.519 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.412 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.51 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . 0.403 ' CG2' ' CG ' ' A' ' 217' ' ' ARG . 6.3 tt -91.21 -29.0 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 125.8 -156.16 19.36 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.3 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 120.634 0.254 . . . . 0.0 110.844 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -118.83 100.89 7.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.372 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.34 -35.24 5.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.865 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -126.56 162.83 24.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 100.22 21.52 13.24 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.488 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 -106.2 27.03 9.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.091 0 CA-C-O 120.841 0.353 . . . . 0.0 110.726 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.6 78.7 1.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 63.2 mt -110.23 147.3 34.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.31 147.02 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.774 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.45 139.48 19.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.076 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.515 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.424 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.402 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.44 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.402 ' CG ' HG23 ' A' ' 234' ' ' THR . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.438 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.44 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.5 p-80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.515 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 18.8 tt -96.96 -25.09 4.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -53.97 130.25 43.35 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.626 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.6 t80 . . . . . 0 C--N 1.327 -0.371 0 CA-C-O 120.674 0.273 . . . . 0.0 110.453 179.819 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -72.93 80.32 1.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.768 0.318 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 61.43 -177.63 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -132.92 162.77 30.73 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 91.53 22.34 31.8 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.567 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.458 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -106.01 26.72 9.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.434 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.813 0.339 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.86 145.27 24.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 83.9 mt -115.03 150.45 35.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.03 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.09 145.94 48.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 50.7 mt -61.94 146.31 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.979 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.503 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.466 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.416 ' CE1' HG12 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.416 HG12 ' CE1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.42 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.42 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.502 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.502 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.457 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.503 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 10.9 tt -82.72 -28.75 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 172.83 -124.17 1.05 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.452 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.617 0.246 . . . . 0.0 110.804 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 61.13 161.12 0.06 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.74 0.305 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -96.47 20.94 9.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.059 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -141.3 162.73 34.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.776 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 78.53 21.2 69.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.615 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.457 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 3.2 mm-40 -105.33 24.61 11.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.778 0.323 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -58.88 161.82 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.894 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 74.0 mt -120.54 158.04 28.15 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.001 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.01 146.2 48.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.792 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt -64.08 140.12 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.977 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.41 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.427 ' CE1' HG13 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.415 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.415 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.444 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.412 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.427 HG13 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.407 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.504 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.504 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.418 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt -88.28 -29.74 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.28 -136.2 12.56 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.528 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.608 0.242 . . . . 0.0 110.943 179.866 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -122.32 -78.66 0.6 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.722 0.296 . . . . 0.0 110.802 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.34 -9.0 10.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.441 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -140.9 162.39 35.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.818 0.342 . . . . 0.0 110.947 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 95.25 -9.59 69.71 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.835 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.449 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 -96.1 29.21 2.86 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 122.878 -0.19 . . . . 0.0 111.027 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.805 0.336 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.7 tt0 -72.91 147.39 45.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 90.9 mt -116.45 144.59 44.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.977 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.17 144.08 44.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.816 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt -60.85 136.32 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.093 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.523 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.423 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.419 ' CZ3' ' O ' ' B' ' 449' ' ' GLU . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.444 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . 0.405 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.514 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.514 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.423 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.523 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 18.8 tt -89.99 -30.18 5.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 76.1 -138.82 23.3 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.471 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.621 0.248 . . . . 0.0 110.797 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.414 0 CA-C-O 120.421 -0.099 . . . . 0.0 112.962 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 58.55 -167.01 0.15 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.835 0.35 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -115.82 169.96 8.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -129.23 163.08 26.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.776 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 83.06 26.0 46.48 Favored Glycine 0 C--N 1.33 0.237 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.414 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.486 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -88.32 19.29 3.86 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.639 0.257 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -116.69 -60.13 1.89 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.02 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 70.0 mt -121.21 158.09 28.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.3 150.92 49.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.774 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt -65.99 143.65 15.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.118 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.532 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.427 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.414 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.414 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.438 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.412 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . 0.411 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.427 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.41 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.526 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.526 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.532 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 16.4 tt -94.83 -25.21 4.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -88.27 -178.04 47.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.363 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.724 0.297 . . . . 0.0 110.746 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.92 117.21 10.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.93 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.32 -42.05 94.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -90.66 162.58 14.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 105.22 -2.52 40.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.642 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.45 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -96.18 25.75 4.69 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.661 0.231 . . . . 0.0 111.056 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.804 0.335 . . . . 0.0 110.986 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -177.59 96.07 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.821 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 77.8 mt -112.47 146.52 38.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.966 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.7 145.16 47.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.704 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt -61.03 140.04 19.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.064 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.538 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.408 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.404 HG22 ' CG ' ' A' ' 241' ' ' TRP . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.447 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.419 ' HB2' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.419 ' CZ2' ' HB2' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.447 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.415 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.543 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.538 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 5.1 tt -88.22 -35.25 7.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 61.68 -89.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.821 -0.705 . . . . 0.0 112.456 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.624 0.25 . . . . 0.0 110.889 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.42 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -116.51 164.16 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.782 0.325 . . . . 0.0 111.001 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.44 32.85 5.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -139.18 162.79 34.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 90.08 18.05 51.52 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.72 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.441 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 -106.13 26.76 9.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.449 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.743 0.306 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.7 179.98 8.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.827 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 79.8 mt -121.76 144.58 48.72 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.894 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.46 145.81 31.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt -65.96 132.19 31.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.041 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . 0.402 ' HD3' ' CG2' ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.526 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.483 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . 0.402 ' CG2' ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.416 HG23 ' CG ' ' A' ' 241' ' ' TRP . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.431 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.424 ' HB3' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.424 ' CZ2' ' HB3' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.445 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.431 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.421 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.421 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.521 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.521 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.526 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 16.3 tt -88.55 -3.46 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.86 74.93 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.473 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 2.5 p90 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.688 0.28 . . . . 0.0 110.795 -179.935 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.18 -53.57 1.83 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -109.09 -31.61 7.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -122.86 162.21 22.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 106.95 -22.17 30.33 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.653 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 -95.16 23.41 5.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.844 0.354 . . . . 0.0 110.799 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.61 -53.1 4.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 81.5 mt -117.23 154.72 30.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.019 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.9 145.84 49.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 31.5 mt -63.94 138.83 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.163 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.531 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.469 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.411 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.457 ' CD1' HG12 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.404 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.431 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . 0.412 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.457 HG12 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.414 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.447 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.523 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.523 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.447 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.531 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 6.5 tt -79.71 -17.48 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 110.14 -164.2 12.33 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.441 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.5 p90 . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.636 0.255 . . . . 0.0 110.841 -179.953 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -62.5 179.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -108.49 78.87 1.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -132.96 162.52 31.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 113.17 -21.85 16.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.665 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.483 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 -96.49 28.91 3.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.901 0.382 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -63.69 169.02 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.847 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 95.2 mt -118.5 150.69 39.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.28 146.68 51.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.782 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 214' ' ' ILE . 62.1 mt -57.0 132.51 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.499 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.419 HG21 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.432 ' CE1' HG13 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.434 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.434 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.411 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.402 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.41 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.432 HG13 ' CE1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.404 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.454 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.454 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.418 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.499 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 2.1 tt -73.89 -30.15 27.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 159.06 105.85 0.22 Allowed Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.556 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 1.2 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.626 0.25 . . . . 0.0 110.872 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -155.49 127.64 7.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -112.39 -41.67 3.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.757 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -90.99 162.66 14.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.791 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 103.34 17.09 18.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.766 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.427 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 -105.37 18.65 21.91 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 122.923 -0.163 . . . . 0.0 110.994 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.76 -27.0 9.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 82.9 mt -107.82 149.39 28.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.838 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 147.69 44.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.718 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 214' ' ' ILE . 48.6 mt -61.8 144.68 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.522 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.418 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.432 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.415 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.429 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.432 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.429 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.518 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.518 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.413 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.522 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 3.6 tt -81.56 -29.0 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 133.92 -123.8 3.41 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.698 0.285 . . . . 0.0 110.858 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 61.11 30.91 19.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.79 0.329 . . . . 0.0 110.964 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -150.74 30.4 0.66 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.753 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -97.03 163.07 13.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 97.8 24.82 11.34 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.459 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.473 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 -101.59 21.84 13.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.823 0.345 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -155.64 178.37 10.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.79 153.76 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 2.5 mtpt -118.27 146.34 44.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . 0.403 HD11 HG23 ' A' ' 214' ' ' ILE . 61.2 mt -63.16 144.61 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.025 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.513 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.418 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.415 ' CD1' HG13 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.415 ' HB1' ' CE1' ' A' ' 236' ' ' PHE . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . . . . . . . . . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.415 HG13 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.525 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.525 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.463 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.513 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt -77.32 -29.41 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.4 -114.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.671 -0.775 . . . . 0.0 112.591 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.675 0.274 . . . . 0.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.5 -172.08 0.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -178.16 -39.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -140.98 162.44 35.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.23 -9.18 63.05 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.91 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.463 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.4 mt-10 -95.83 28.71 2.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.702 0.251 . . . . 0.0 110.974 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.453 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 62.47 -174.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 31.4 mt -120.32 145.83 46.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.85 140.77 36.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 44.4 mt -61.94 148.98 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.004 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.517 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.413 HG22 ' CG ' ' A' ' 241' ' ' TRP . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.43 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.421 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.421 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.421 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.426 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . 0.4 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.43 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.406 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.521 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.521 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.517 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 20.1 tt -88.73 -29.41 5.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -67.9 118.39 9.62 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.426 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 4.9 p90 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.621 0.248 . . . . 0.0 110.965 179.936 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.436 0 N-CA-C 112.579 -0.208 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -131.12 55.18 1.86 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.799 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -171.64 -41.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -125.58 162.44 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.845 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 102.19 -9.4 56.22 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.746 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.485 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 -95.45 30.89 2.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.667 0.234 . . . . 0.0 111.041 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.841 0.353 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.15 -58.72 3.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.792 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 44.3 mt -122.38 149.49 43.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.56 144.91 41.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.843 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt -65.24 141.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.081 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . 0.4 ' CG ' ' CG2' ' A' ' 281' ' ' ILE . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.509 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.402 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.437 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.403 ' HB2' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.403 ' CZ2' ' HB2' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . 0.4 ' CA ' ' CD1' ' A' ' 246' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.437 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.496 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.496 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.509 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . 0.4 ' CG2' ' CG ' ' A' ' 217' ' ' ARG . 11.5 tt -94.79 -29.71 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -156.46 141.38 7.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.622 0.249 . . . . 0.0 110.964 -179.926 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.549 -0.22 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -133.57 112.92 11.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.772 0.32 . . . . 0.0 110.959 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.81 175.72 9.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -137.89 162.71 33.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.7 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 66.28 25.75 72.46 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.444 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 -94.51 27.06 3.13 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.762 0.315 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -64.93 -31.82 73.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.933 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 46.2 mt -121.83 149.68 42.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.27 143.14 37.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.781 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . 0.445 HD11 HG21 ' A' ' 214' ' ' ILE . 38.7 mt -64.53 148.74 11.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.929 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.505 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.425 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . 0.427 ' HB3' ' CE2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.427 ' CE2' ' HB3' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.422 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.425 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.412 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.422 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.497 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.497 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.446 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.505 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 11.8 tt -96.8 -30.9 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -93.02 73.81 1.3 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.555 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.235 0 CA-C-O 120.669 0.271 . . . . 0.0 110.895 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.186 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -88.67 -75.5 0.43 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.881 0.372 . . . . 0.0 110.826 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -74.4 -35.74 63.47 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -98.04 162.59 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.788 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 112.85 2.7 25.29 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.752 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.46 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 -97.51 29.31 3.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.669 0.234 . . . . 0.0 110.948 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.443 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.757 0.313 . . . . 0.0 110.964 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -154.24 138.76 16.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.907 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 66.5 mt -107.31 142.15 37.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.855 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.76 146.64 50.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 5.5 mt -58.13 143.24 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.985 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.519 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.418 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.415 HG22 ' CG ' ' A' ' 241' ' ' TRP . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.435 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . 0.415 ' CG ' HG22 ' A' ' 234' ' ' THR . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.433 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.435 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 7.6 tp60 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.509 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.509 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.47 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.519 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt -83.19 -28.52 7.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 98.71 -112.99 4.6 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.375 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 . . . . . 0 C--N 1.329 -0.326 0 CA-C-O 120.681 0.277 . . . . 0.0 110.869 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.542 -0.223 . . . . 0.0 112.542 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.36 106.97 12.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.904 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.92 74.26 1.05 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.755 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 -141.22 162.61 35.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.889 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 74.42 20.7 79.53 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.706 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.6 mt-10 -106.13 23.15 14.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.542 0.171 . . . . 0.0 111.038 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.848 0.356 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -153.55 162.94 40.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.57 147.56 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.934 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.96 148.5 52.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 4.1 mt -59.38 138.92 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.891 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 218' ' ' VAL . . . . . 0.536 ' CG2' ' CG1' ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 220' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.422 ' CB ' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' PHE . . . . . 0.446 ' CD1' ' CG1' ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' GLY . . . . . 0.432 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' LEU . . . . . 0.407 ' O ' ' CD2' ' A' ' 269' ' ' TYR . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' GLU . . . . . 0.404 ' CB ' ' CD2' ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . 0.403 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' LEU . . . . . 0.404 ' CD2' ' CB ' ' A' ' 248' ' ' GLU . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' GLY . . . . . . . . . . . . . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.446 ' CG1' ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' LEU . . . . . . . . . . . . . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' ALA . . . . . . . . . . . . . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' PRO . . . . . 0.492 ' HB2' ' CD2' ' A' ' 276' ' ' HIS . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' HIS . . . . . 0.492 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' VAL . . . . . 0.536 ' CG1' ' CG2' ' A' ' 218' ' ' VAL . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt -77.97 -27.48 14.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.38 26.68 8.56 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.59 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.628 0.251 . . . . 0.0 110.919 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.13 -62.46 0.06 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -101.01 28.77 5.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -141.22 162.66 34.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 70.28 18.12 74.77 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.783 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 449' ' ' GLU . . . . . 0.455 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 0.8 OUTLIER -99.63 26.0 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 450' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 451' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.637 HG23 ' HA ' ' A' ' 229' ' ' ARG . 7.2 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.909 0.385 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.58 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.661 HG21 HG11 ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.843 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.452 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.468 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.637 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.651 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.401 ' HB2' HG23 ' A' ' 234' ' ' THR . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.455 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.462 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.414 HD21 HD22 ' A' ' 271' ' ' LEU . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.878 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.651 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.405 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 2.7 mm100 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.878 HD13 ' HA2' ' A' ' 251' ' ' GLY . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.843 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.71 ' O ' HG23 ' A' ' 278' ' ' VAL . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.533 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.475 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.71 HG23 ' O ' ' A' ' 274' ' ' PRO . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.445 HD12 HD21 ' A' ' 219' ' ' LEU . 12.9 tt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.508 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 120.474 0.178 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.4 ' O ' HD12 ' A' ' 271' ' ' LEU . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.546 HG23 ' HA ' ' A' ' 229' ' ' ARG . 51.9 mt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.97 0.414 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.427 ' HD3' HG22 ' A' ' 227' ' ' VAL . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.427 HG22 ' HD3' ' A' ' 217' ' ' ARG . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.546 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.52 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.656 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.529 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.52 ' SG ' HD23 ' A' ' 231' ' ' LEU . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.464 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.401 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.482 HD22 ' CD1' ' A' ' 250' ' ' LEU . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.767 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.868 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.656 ' O ' HG23 ' A' ' 278' ' ' VAL . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.471 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.4 p80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.4 HD12 HD21 ' A' ' 219' ' ' LEU . 8.7 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.47 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.614 ' O ' HD12 ' A' ' 271' ' ' LEU . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.764 0.316 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.522 ' HG2' HG21 ' A' ' 281' ' ' ILE . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.701 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.854 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.438 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.4 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.654 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.61 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.654 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.428 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.4 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.454 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.434 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.484 HD22 ' CD1' ' A' ' 250' ' ' LEU . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.432 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.484 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.809 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.61 HG11 ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 261' ' ' ARG . . . . . 0.408 ' NH1' ' HB3' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.432 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.809 HD13 ' HA2' ' A' ' 251' ' ' GLY . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.854 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.697 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.512 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.701 HG11 HG21 ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.522 HG21 ' HG2' ' A' ' 217' ' ' ARG . 2.2 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.507 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 . . . . . 0 CA--C 1.523 -0.075 0 CA-C-O 120.387 0.137 . . . . 0.0 111.146 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.658 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.678 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.2 mt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.879 0.371 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.441 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.702 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.559 HD21 HD12 ' A' ' 281' ' ' ILE . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.877 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.441 HG22 ' HD3' ' A' ' 217' ' ' ARG . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.419 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.678 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.523 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.601 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.614 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.601 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.454 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.523 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.45 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 250' ' ' LEU . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.765 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.614 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.431 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.877 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.857 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.776 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.511 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 274' ' ' PRO . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.559 HD12 HD21 ' A' ' 219' ' ' LEU . 6.3 tt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.545 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.693 HD13 HG12 ' A' ' 228' ' ' VAL . 31.6 mm . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.795 0.331 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.439 ' HD3' HG22 ' A' ' 227' ' ' VAL . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.985 HD21 HD12 ' A' ' 281' ' ' ILE . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.565 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.439 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.693 HG12 HD13 ' A' ' 214' ' ' ILE . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.419 ' C ' HD12 ' A' ' 214' ' ' ILE . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 230' ' ' PHE . . . . . 0.435 ' N ' HD12 ' A' ' 214' ' ' ILE . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.553 HD12 HD11 ' A' ' 214' ' ' ILE . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.53 ' SG ' HD23 ' A' ' 231' ' ' LEU . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.481 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.407 HD12 ' CA ' ' A' ' 251' ' ' GLY . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.44 ' HB3' HD23 ' A' ' 250' ' ' LEU . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.565 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.713 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.402 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.852 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.718 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.511 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.9 p80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.401 ' CD ' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 274' ' ' PRO . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.985 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.521 -0.138 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 229' ' ' ARG . 50.7 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.891 0.377 . . . . 0.0 110.979 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.697 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.892 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.45 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.697 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.407 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.489 ' HA ' HG23 ' A' ' 214' ' ' ILE . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.501 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.663 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.663 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.476 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.501 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.471 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.433 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.682 HD22 ' CD1' ' A' ' 250' ' ' LEU . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.682 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.769 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.632 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.892 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.862 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.701 ' O ' HG23 ' A' ' 278' ' ' VAL . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.435 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 274' ' ' PRO . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.404 HD12 HD21 ' A' ' 219' ' ' LEU . 10.9 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mm-40 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.627 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.82 0.343 . . . . 0.0 110.977 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.457 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.706 HG21 HG11 ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.608 HD21 HD12 ' A' ' 281' ' ' ILE . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.899 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.452 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.446 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.457 HG22 ' HD3' ' A' ' 217' ' ' ARG . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.537 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.591 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.591 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.683 HD22 ' CD1' ' A' ' 250' ' ' LEU . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.683 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.784 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.889 HD23 ' HB ' ' A' ' 220' ' ' VAL . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.899 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.737 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.541 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.608 HD12 HD21 ' A' ' 219' ' ' LEU . 13.6 tt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 120.497 0.189 . . . . 0.0 111.027 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.566 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.731 0.301 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.696 ' HD3' HG22 ' A' ' 227' ' ' VAL . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.654 HG21 HG11 ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.616 HD21 HD12 ' A' ' 281' ' ' ILE . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.578 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.696 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.652 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.672 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.652 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.461 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.488 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.476 HD11 HD22 ' A' ' 271' ' ' LEU . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.463 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.578 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.776 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.672 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.436 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.436 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.845 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.722 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.522 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.3 p80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.616 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.516 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER . . . . . 0 C--O 1.227 -0.104 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.643 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.868 0.366 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.525 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.698 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.706 HD21 HD12 ' A' ' 281' ' ' ILE . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.874 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.58 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.494 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.625 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.69 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.625 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.471 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.494 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.46 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.438 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.422 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.58 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.685 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.69 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.874 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.694 ' O ' HG23 ' A' ' 278' ' ' VAL . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.491 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.5 p80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.458 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.698 HG11 HG21 ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.706 HD12 HD21 ' A' ' 219' ' ' LEU . 16.4 tt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.435 0.16 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.448 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.788 0.328 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.671 HG21 HG11 ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 281' ' ' ILE . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.458 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.446 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.535 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.607 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.535 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.493 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.446 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.427 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.637 HD22 ' CD1' ' A' ' 250' ' ' LEU . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.431 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.637 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.84 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.607 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.866 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.745 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.528 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.1 p80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.492 HD12 HD21 ' A' ' 219' ' ' LEU . 5.1 tt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.474 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.787 0.327 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.6 ' HD3' HG22 ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.44 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HA ' HD23 ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.6 HG22 ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.457 HG13 ' SG ' ' A' ' 242' ' ' CYS . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.487 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.457 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.507 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.436 HD21 HD22 ' A' ' 271' ' ' LEU . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 250' ' ' LEU . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.44 HD12 ' HD3' ' A' ' 224' ' ' LYS . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.788 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.86 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.532 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.2 p80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.449 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.419 HG21 ' CG ' ' A' ' 217' ' ' ARG . 16.3 tt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.518 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 . . . . . 0 CA--C 1.521 -0.157 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.415 HG23 ' HA ' ' A' ' 229' ' ' ARG . 31.5 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.761 0.315 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.613 ' HD3' HG22 ' A' ' 227' ' ' VAL . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.658 HG21 HG11 ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 281' ' ' ILE . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.531 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.45 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.613 HG22 ' HD3' ' A' ' 217' ' ' ARG . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.415 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.504 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.471 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.543 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.404 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.504 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.468 HD12 ' CA ' ' A' ' 251' ' ' GLY . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.468 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.531 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.697 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.471 HG11 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.453 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.853 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.725 ' O ' HG23 ' A' ' 278' ' ' VAL . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.496 ' CE1' ' HB2' ' A' ' 274' ' ' PRO . 2.1 p80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.467 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.518 HD12 HD21 ' A' ' 219' ' ' LEU . 6.5 tt . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.676 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.703 HG23 ' HA ' ' A' ' 229' ' ' ARG . 62.1 mt . . . . . 0 N--CA 1.456 -0.148 0 CA-C-O 120.816 0.341 . . . . 0.0 110.988 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.469 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.618 HG21 HG11 ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.638 HD21 HD12 ' A' ' 281' ' ' ILE . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.89 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.422 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.469 HG22 ' HD3' ' A' ' 217' ' ' ARG . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.448 HG13 ' SG ' ' A' ' 242' ' ' CYS . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.473 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.44 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.473 ' CG ' HG23 ' A' ' 234' ' ' THR . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.448 ' SG ' HG13 ' A' ' 228' ' ' VAL . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.456 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.547 HD13 HD12 ' A' ' 250' ' ' LEU . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.424 ' CB ' HD23 ' A' ' 250' ' ' LEU . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.547 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.758 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.89 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.792 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.47 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.47 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 274' ' ' PRO . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.618 HG11 HG21 ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.638 HD12 HD21 ' A' ' 219' ' ' LEU . 2.1 tt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.457 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 . . . . . 0 CA--C 1.521 -0.137 0 CA-C-O 120.387 0.137 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.582 ' O ' HD12 ' A' ' 271' ' ' LEU . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.476 HG23 ' HA ' ' A' ' 229' ' ' ARG . 48.6 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.864 0.364 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.567 ' HD3' HG22 ' A' ' 227' ' ' VAL . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.663 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 281' ' ' ILE . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.848 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.408 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.455 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.567 HG22 ' HD3' ' A' ' 217' ' ' ARG . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.476 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.522 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.57 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.522 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.446 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.562 HD22 ' CD1' ' A' ' 250' ' ' LEU . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.562 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.57 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.847 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.848 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.719 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.519 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.3 p80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 219' ' ' LEU . 3.6 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.504 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 . . . . . 0 CA--C 1.522 -0.112 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.572 ' O ' HD12 ' A' ' 271' ' ' LEU . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.592 HG23 ' HA ' ' A' ' 229' ' ' ARG . 61.2 mt . . . . . 0 CA--C 1.528 0.122 0 CA-C-O 120.78 0.324 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.524 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.856 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.403 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.524 HG22 ' HD3' ' A' ' 217' ' ' ARG . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.592 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.537 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.752 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.522 ' CE1' HG11 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.752 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.497 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.441 HD22 ' CD1' ' A' ' 250' ' ' LEU . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.441 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.522 HG11 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.856 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.856 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.759 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.53 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.2 p80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.485 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 274' ' ' PRO . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.485 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.4 mt-10 . . . . . 0 N--CA 1.46 0.072 0 CA-C-O 120.451 0.167 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.587 ' O ' HD12 ' A' ' 271' ' ' LEU . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.435 HG23 ' HA ' ' A' ' 229' ' ' ARG . 44.4 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.898 0.38 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.696 HG21 HG11 ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.887 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.456 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.457 ' HB2' HD22 ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.421 HG11 HD21 ' A' ' 231' ' ' LEU . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.595 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.567 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.654 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.567 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.468 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.595 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.566 HD22 ' CD1' ' A' ' 250' ' ' LEU . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.566 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.803 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.654 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.419 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.875 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.471 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.5 p80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.425 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.451 HD12 HD21 ' A' ' 219' ' ' LEU . 20.1 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 . . . . . 0 CA--C 1.521 -0.155 0 CA-C-O 120.372 0.13 . . . . 0.0 111.041 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.528 ' O ' HD12 ' A' ' 271' ' ' LEU . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.853 0.359 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.531 ' HD3' HG22 ' A' ' 227' ' ' VAL . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.692 HG21 HG11 ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.791 HD21 HD12 ' A' ' 281' ' ' ILE . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.441 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.408 ' HA3' HG12 ' A' ' 244' ' ' VAL . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.531 HG22 ' HD3' ' A' ' 217' ' ' ARG . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 228' ' ' VAL . . . . . 0.433 HG13 ' SG ' ' A' ' 242' ' ' CYS . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.682 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 240' ' ' GLU . . . . . 0.404 ' OE1' HG21 ' A' ' 275' ' ' VAL . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.535 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.433 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.408 HG12 ' HA3' ' A' ' 226' ' ' GLY . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.603 HD22 ' CD1' ' A' ' 250' ' ' LEU . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.436 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.603 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.771 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.682 HG11 ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.401 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.897 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.721 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 275' ' ' VAL . . . . . 0.404 HG21 ' OE1' ' A' ' 240' ' ' GLU . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.422 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.462 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.791 HD12 HD21 ' A' ' 219' ' ' LEU . 11.5 tt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.475 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.604 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 38.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.92 0.391 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.55 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.705 HG21 HG11 ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.724 HD21 HD12 ' A' ' 281' ' ' ILE . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.475 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.603 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.432 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.432 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.475 ' SG ' HD23 ' A' ' 231' ' ' LEU . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.439 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.467 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.464 HD13 HD12 ' A' ' 250' ' ' LEU . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.464 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.8 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 256' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.603 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 261' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.424 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.424 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.88 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.76 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.489 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.7 p80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 281' ' ' ILE . . . . . 0.724 HD12 HD21 ' A' ' 219' ' ' LEU . 11.8 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 . . . . . 0 CA--C 1.522 -0.124 0 CA-C-O 120.58 0.229 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.584 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.669 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.5 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.816 0.341 . . . . 0.0 110.985 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.599 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.672 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.458 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.486 ' HG3' HD21 ' A' ' 271' ' ' LEU . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.599 HG22 ' HD3' ' A' ' 217' ' ' ARG . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.669 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.604 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.664 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.664 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.481 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.604 ' SG ' HD23 ' A' ' 231' ' ' LEU . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 244' ' ' VAL . . . . . 0.447 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.511 HD22 ' CD1' ' A' ' 250' ' ' LEU . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.511 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.759 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 266' ' ' GLN . . . . . 0.4 ' HG3' ' HD2' ' A' ' 267' ' ' PRO . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 267' ' ' PRO . . . . . 0.4 ' HD2' ' HG3' ' A' ' 266' ' ' GLN . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.861 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.716 ' O ' HG23 ' A' ' 278' ' ' VAL . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.424 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 274' ' ' PRO . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.6 mt-10 . . . . . 0 CA--C 1.521 -0.136 0 CA-C-O 120.425 0.155 . . . . 0.0 111.038 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.649 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 214' ' ' ILE . . . . . 0.737 HG23 ' HA ' ' A' ' 229' ' ' ARG . 4.1 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.789 0.328 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 217' ' ' ARG . . . . . 0.63 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 218' ' ' VAL . . . . . 0.721 HG21 HG11 ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 219' ' ' LEU . . . . . 0.466 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 220' ' ' VAL . . . . . 0.89 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 224' ' ' LYS . . . . . 0.572 ' HE2' HD13 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 227' ' ' VAL . . . . . 0.63 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 229' ' ' ARG . . . . . 0.737 ' HA ' HG23 ' A' ' 214' ' ' ILE . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.542 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 234' ' ' THR . . . . . 0.608 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 236' ' ' PHE . . . . . 0.611 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 237' ' ' ALA . . . . . 0.608 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 242' ' ' CYS . . . . . 0.542 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 243' ' ' GLY . . . . . 0.452 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 246' ' ' LEU . . . . . 0.436 HD12 ' CA ' ' A' ' 251' ' ' GLY . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 248' ' ' GLU . . . . . 0.429 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 250' ' ' LEU . . . . . 0.572 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 251' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.611 HG11 ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 271' ' ' LEU . . . . . 0.874 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 273' ' ' ALA . . . . . 0.89 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 274' ' ' PRO . . . . . 0.726 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 276' ' ' HIS . . . . . 0.427 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.2 p80 -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 277' ' ' LYS . . . . . 0.454 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 278' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 449' ' ' GLU . . . . . 0.479 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER . . . . . 0 CA--C 1.523 -0.094 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 451' ' ' TYR . . . . . 0.619 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.3 mtt85 . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -71.17 -169.08 0.35 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.904 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.46 HD22 HG11 ' A' ' 218' ' ' VAL . 78.7 mt -104.36 150.77 24.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.24 144.82 50.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.637 HG23 ' HA ' ' A' ' 229' ' ' ARG . 7.2 mt -58.8 139.67 18.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.92 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.58 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.661 HG21 HG11 ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.843 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.452 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.468 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.637 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.651 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.401 ' HB2' HG23 ' A' ' 234' ' ' THR . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.455 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.462 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.414 HD21 HD22 ' A' ' 271' ' ' LEU . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.878 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.651 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.405 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 2.7 mm100 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.878 HD13 ' HA2' ' A' ' 251' ' ' GLY . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.843 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.71 ' O ' HG23 ' A' ' 278' ' ' VAL . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.533 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.475 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.71 HG23 ' O ' ' A' ' 274' ' ' PRO . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.445 HD12 HD21 ' A' ' 219' ' ' LEU . 12.9 tt -80.91 -30.07 11.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.69 80.42 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.463 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 C--N 1.328 -0.369 0 CA-C-O 120.703 0.287 . . . . 0.0 110.862 -179.906 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -99.52 35.87 1.88 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.862 0.363 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 63.52 140.42 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 34.2 mm-40 -140.99 162.65 34.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.82 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.39 17.9 44.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.668 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.508 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 -106.12 25.34 11.11 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 122.894 -0.18 . . . . 0.0 110.96 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.4 ' O ' HD12 ' A' ' 271' ' ' LEU . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.751 0.31 . . . . 0.0 110.918 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -59.44 -77.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 218' ' ' VAL . 78.2 mt -114.49 146.3 40.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -132.38 148.15 52.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.696 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.546 HG23 ' HA ' ' A' ' 229' ' ' ARG . 51.9 mt -60.06 135.45 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.899 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.427 ' HD3' HG22 ' A' ' 227' ' ' VAL . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.427 HG22 ' HD3' ' A' ' 217' ' ' ARG . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.546 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.52 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.656 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.529 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.52 ' SG ' HD23 ' A' ' 231' ' ' LEU . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.464 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.401 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.482 HD22 ' CD1' ' A' ' 250' ' ' LEU . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.767 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.868 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.656 ' O ' HG23 ' A' ' 278' ' ' VAL . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.471 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.4 p80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.4 HD12 HD21 ' A' ' 219' ' ' LEU . 8.7 tt -72.58 -23.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -130.29 53.89 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.4 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 5.5 t80 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.64 0.257 . . . . 0.0 110.843 -179.889 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -155.09 -48.39 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.796 0.331 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 -133.58 31.82 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.809 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -113.88 162.73 16.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.864 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.14 16.41 50.65 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.639 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.47 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 -106.18 29.49 6.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.614 ' O ' HD12 ' A' ' 271' ' ' LEU . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.79 0.328 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -78.54 155.32 29.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 36.3 mt -121.94 151.73 40.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.793 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.03 141.59 42.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.945 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt -63.28 142.69 16.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.141 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.522 ' HG2' HG21 ' A' ' 281' ' ' ILE . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.701 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.854 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.438 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.4 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.654 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.61 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.654 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.428 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.4 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.454 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.434 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.484 HD22 ' CD1' ' A' ' 250' ' ' LEU . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.432 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.484 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.809 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.61 HG11 ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' ARG . . . . . 0.408 ' NH1' ' HB3' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.432 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.809 HD13 ' HA2' ' A' ' 251' ' ' GLY . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.854 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.697 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.512 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.701 HG11 HG21 ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.522 HG21 ' HG2' ' A' ' 217' ' ' ARG . 2.2 tt -68.75 -25.56 30.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -58.55 -165.99 0.12 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.481 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 10.6 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.604 0.24 . . . . 0.0 110.865 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.37 73.57 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.912 0.386 . . . . 0.0 110.889 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -99.33 83.66 2.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -139.53 162.46 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.83 -8.17 61.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.823 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.507 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 -94.04 20.75 7.49 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 122.855 -0.203 . . . . 0.0 111.146 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.658 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.869 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -136.16 169.35 17.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.558 HD22 HG11 ' A' ' 218' ' ' VAL . 76.2 mt -114.61 157.91 22.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.47 145.35 45.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.678 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.2 mt -58.17 137.63 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.059 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.441 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.702 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.559 HD21 HD12 ' A' ' 281' ' ' ILE . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.877 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.441 HG22 ' HD3' ' A' ' 217' ' ' ARG . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.419 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.678 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.523 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.601 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.614 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.601 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.454 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.523 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.45 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 250' ' ' LEU . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.765 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.614 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.431 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.877 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.857 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.776 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.511 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.0 p80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 274' ' ' PRO . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.559 HD12 HD21 ' A' ' 219' ' ' LEU . 6.3 tt -91.21 -29.0 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 125.8 -156.16 19.36 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.3 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 120.634 0.254 . . . . 0.0 110.844 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -118.83 100.89 7.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.372 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.34 -35.24 5.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.865 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -126.56 162.83 24.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 100.22 21.52 13.24 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.488 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 -106.2 27.03 9.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.545 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 210' ' ' ARG . . . . . 0.559 HH12 HG23 ' A' ' 279' ' ' THR . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.091 0 CA-C-O 120.841 0.353 . . . . 0.0 110.726 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.6 78.7 1.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 63.2 mt -110.23 147.3 34.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.31 147.02 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.774 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.693 HD13 HG12 ' A' ' 228' ' ' VAL . 31.6 mm -59.45 139.48 19.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.076 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.439 ' HD3' HG22 ' A' ' 227' ' ' VAL . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.985 HD21 HD12 ' A' ' 281' ' ' ILE . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.565 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.439 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.693 HG12 HD13 ' A' ' 214' ' ' ILE . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.419 ' C ' HD12 ' A' ' 214' ' ' ILE . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 230' ' ' PHE . . . . . 0.435 ' N ' HD12 ' A' ' 214' ' ' ILE . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.553 HD12 HD11 ' A' ' 214' ' ' ILE . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.53 ' SG ' HD23 ' A' ' 231' ' ' LEU . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.481 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.407 HD12 ' CA ' ' A' ' 251' ' ' GLY . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.44 ' HB3' HD23 ' A' ' 250' ' ' LEU . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.565 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.713 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.402 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.852 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.718 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 275' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 210' ' ' ARG . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.511 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.9 p80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.401 ' CD ' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 274' ' ' PRO . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' THR . . . . . 0.559 HG23 HH12 ' A' ' 210' ' ' ARG . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.985 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt -96.96 -25.09 4.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -53.97 130.25 43.35 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.626 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.6 t80 . . . . . 0 C--N 1.327 -0.371 0 CA-C-O 120.674 0.273 . . . . 0.0 110.453 179.819 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -72.93 80.32 1.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.768 0.318 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 61.43 -177.63 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -132.92 162.77 30.73 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 91.53 22.34 31.8 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.567 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -106.01 26.72 9.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.813 0.339 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.86 145.27 24.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.441 HD11 ' HB ' ' A' ' 278' ' ' VAL . 83.9 mt -115.03 150.45 35.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.03 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.09 145.94 48.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 229' ' ' ARG . 50.7 mt -61.94 146.31 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.979 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.697 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.892 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.45 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.697 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.407 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.489 ' HA ' HG23 ' A' ' 214' ' ' ILE . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.501 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.663 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.663 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.476 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.501 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.471 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.433 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.682 HD22 ' CD1' ' A' ' 250' ' ' LEU . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.682 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.769 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.632 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.892 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.862 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.701 ' O ' HG23 ' A' ' 278' ' ' VAL . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.435 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 274' ' ' PRO . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.404 HD12 HD21 ' A' ' 219' ' ' LEU . 10.9 tt -82.72 -28.75 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 172.83 -124.17 1.05 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.452 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.617 0.246 . . . . 0.0 110.804 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 61.13 161.12 0.06 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.74 0.305 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -96.47 20.94 9.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.059 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -141.3 162.73 34.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.776 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 78.53 21.2 69.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.615 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mm-40 -105.33 24.61 11.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.627 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.778 0.323 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -58.88 161.82 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.894 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 74.0 mt -120.54 158.04 28.15 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.001 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.01 146.2 48.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.792 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt -64.08 140.12 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.977 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.457 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.706 HG21 HG11 ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.608 HD21 HD12 ' A' ' 281' ' ' ILE . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.899 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.452 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.446 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.457 HG22 ' HD3' ' A' ' 217' ' ' ARG . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.537 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.591 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.591 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.683 HD22 ' CD1' ' A' ' 250' ' ' LEU . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.683 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.784 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.889 HD23 ' HB ' ' A' ' 220' ' ' VAL . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.899 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.737 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.541 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.608 HD12 HD21 ' A' ' 219' ' ' LEU . 13.6 tt -88.28 -29.74 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.28 -136.2 12.56 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.528 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.608 0.242 . . . . 0.0 110.943 179.866 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -122.32 -78.66 0.6 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.722 0.296 . . . . 0.0 110.802 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.34 -9.0 10.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.441 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -140.9 162.39 35.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.818 0.342 . . . . 0.0 110.947 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 95.25 -9.59 69.71 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.835 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 -96.1 29.21 2.86 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 122.878 -0.19 . . . . 0.0 111.027 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.566 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.805 0.336 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.7 tt0 -72.91 147.39 45.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.525 HD22 HG11 ' A' ' 218' ' ' VAL . 90.9 mt -116.45 144.59 44.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.977 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.17 144.08 44.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.816 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt -60.85 136.32 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.093 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.696 ' HD3' HG22 ' A' ' 227' ' ' VAL . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.654 HG21 HG11 ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.616 HD21 HD12 ' A' ' 281' ' ' ILE . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.578 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.696 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.652 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.672 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.652 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.461 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.488 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.476 HD11 HD22 ' A' ' 271' ' ' LEU . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.463 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.578 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.776 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.672 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.436 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.436 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.845 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.722 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.522 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.3 p80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.616 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt -89.99 -30.18 5.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 76.1 -138.82 23.3 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.471 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.621 0.248 . . . . 0.0 110.797 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.414 0 CA-C-O 120.421 -0.099 . . . . 0.0 112.962 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 58.55 -167.01 0.15 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.835 0.35 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -115.82 169.96 8.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -129.23 163.08 26.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.776 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 83.06 26.0 46.48 Favored Glycine 0 C--N 1.33 0.237 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.414 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.516 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -88.32 19.29 3.86 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.643 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.639 0.257 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -116.69 -60.13 1.89 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.02 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.543 HD22 HG11 ' A' ' 218' ' ' VAL . 70.0 mt -121.21 158.09 28.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.172 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.3 150.92 49.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.774 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt -65.99 143.65 15.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.118 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.525 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.698 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.706 HD21 HD12 ' A' ' 281' ' ' ILE . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.874 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.58 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.494 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.625 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.69 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.625 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.471 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.494 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.46 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.438 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.422 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.58 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.685 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.69 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.874 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.694 ' O ' HG23 ' A' ' 278' ' ' VAL . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.491 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.5 p80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.458 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.698 HG11 HG21 ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.706 HD12 HD21 ' A' ' 219' ' ' LEU . 16.4 tt -94.83 -25.21 4.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -88.27 -178.04 47.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.363 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.724 0.297 . . . . 0.0 110.746 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.92 117.21 10.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.93 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.32 -42.05 94.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -90.66 162.58 14.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 105.22 -2.52 40.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.642 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -96.18 25.75 4.69 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.661 0.231 . . . . 0.0 111.056 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.448 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' ARG . . . . . 0.483 ' CG ' HG22 ' A' ' 275' ' ' VAL . 1.5 tpm_? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.804 0.335 . . . . 0.0 110.986 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -177.59 96.07 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.821 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 77.8 mt -112.47 146.52 38.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.966 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.7 145.16 47.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.704 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt -61.03 140.04 19.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.064 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.671 HG21 HG11 ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 281' ' ' ILE . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.458 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.446 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.535 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.607 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.535 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.493 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.446 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.427 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.637 HD22 ' CD1' ' A' ' 250' ' ' LEU . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.431 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.637 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.84 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.607 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.866 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.745 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 275' ' ' VAL . . . . . 0.483 HG22 ' CG ' ' A' ' 210' ' ' ARG . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.528 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.1 p80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.492 HD12 HD21 ' A' ' 219' ' ' LEU . 5.1 tt -88.22 -35.25 7.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 61.68 -89.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.821 -0.705 . . . . 0.0 112.456 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.624 0.25 . . . . 0.0 110.889 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.42 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -116.51 164.16 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.782 0.325 . . . . 0.0 111.001 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.44 32.85 5.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -139.18 162.79 34.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 90.08 18.05 51.52 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.72 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.474 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 -106.13 26.76 9.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.743 0.306 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.7 179.98 8.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.827 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 79.8 mt -121.76 144.58 48.72 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.894 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.46 145.81 31.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt -65.96 132.19 31.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.041 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.6 ' HD3' HG22 ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.44 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HA ' HD23 ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.6 HG22 ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.457 HG13 ' SG ' ' A' ' 242' ' ' CYS . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.487 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.457 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.507 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.436 HD21 HD22 ' A' ' 271' ' ' LEU . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 250' ' ' LEU . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.44 HD12 ' HD3' ' A' ' 224' ' ' LYS . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.788 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.86 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.532 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.2 p80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.449 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.419 HG21 ' CG ' ' A' ' 217' ' ' ARG . 16.3 tt -88.55 -3.46 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.86 74.93 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.473 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 2.5 p90 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.688 0.28 . . . . 0.0 110.795 -179.935 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.18 -53.57 1.83 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -109.09 -31.61 7.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -122.86 162.21 22.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 106.95 -22.17 30.33 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.653 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.518 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 -95.16 23.41 5.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.844 0.354 . . . . 0.0 110.799 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.61 -53.1 4.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 81.5 mt -117.23 154.72 30.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.019 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.9 145.84 49.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.415 HG23 ' HA ' ' A' ' 229' ' ' ARG . 31.5 mt -63.94 138.83 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.163 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.613 ' HD3' HG22 ' A' ' 227' ' ' VAL . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.658 HG21 HG11 ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 281' ' ' ILE . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.531 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.45 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.613 HG22 ' HD3' ' A' ' 217' ' ' ARG . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.415 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.504 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.471 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.543 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.404 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.504 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.468 HD12 ' CA ' ' A' ' 251' ' ' GLY . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.468 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.531 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.697 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.471 HG11 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.453 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.853 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.725 ' O ' HG23 ' A' ' 278' ' ' VAL . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.496 ' CE1' ' HB2' ' A' ' 274' ' ' PRO . 2.1 p80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.467 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.518 HD12 HD21 ' A' ' 219' ' ' LEU . 6.5 tt -79.71 -17.48 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 110.14 -164.2 12.33 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.441 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.5 p90 . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.636 0.255 . . . . 0.0 110.841 -179.953 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -62.5 179.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -108.49 78.87 1.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -132.96 162.52 31.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 113.17 -21.85 16.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.665 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 -96.49 28.91 3.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.676 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.901 0.382 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -63.69 169.02 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.847 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.487 HD22 HG11 ' A' ' 218' ' ' VAL . 95.2 mt -118.5 150.69 39.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.28 146.68 51.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.782 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.703 HG23 ' HA ' ' A' ' 229' ' ' ARG . 62.1 mt -57.0 132.51 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.469 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.618 HG21 HG11 ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.638 HD21 HD12 ' A' ' 281' ' ' ILE . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.89 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.422 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.469 HG22 ' HD3' ' A' ' 217' ' ' ARG . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.448 HG13 ' SG ' ' A' ' 242' ' ' CYS . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.473 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.44 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.473 ' CG ' HG23 ' A' ' 234' ' ' THR . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.448 ' SG ' HG13 ' A' ' 228' ' ' VAL . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.456 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.547 HD13 HD12 ' A' ' 250' ' ' LEU . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.424 ' CB ' HD23 ' A' ' 250' ' ' LEU . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.547 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.758 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.89 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.792 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.47 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.47 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 274' ' ' PRO . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.618 HG11 HG21 ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.638 HD12 HD21 ' A' ' 219' ' ' LEU . 2.1 tt -73.89 -30.15 27.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 159.06 105.85 0.22 Allowed Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.556 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 1.2 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.626 0.25 . . . . 0.0 110.872 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -155.49 127.64 7.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -112.39 -41.67 3.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.757 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -90.99 162.66 14.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.791 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 103.34 17.09 18.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.766 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.457 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 -105.37 18.65 21.91 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 122.923 -0.163 . . . . 0.0 110.994 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.582 ' O ' HD12 ' A' ' 271' ' ' LEU . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.76 -27.0 9.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 82.9 mt -107.82 149.39 28.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.838 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 147.69 44.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.718 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.476 HG23 ' HA ' ' A' ' 229' ' ' ARG . 48.6 mt -61.8 144.68 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.567 ' HD3' HG22 ' A' ' 227' ' ' VAL . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.663 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 281' ' ' ILE . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.848 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.408 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.455 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.567 HG22 ' HD3' ' A' ' 217' ' ' ARG . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.476 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.522 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.57 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.522 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.446 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.562 HD22 ' CD1' ' A' ' 250' ' ' LEU . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.562 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.57 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.847 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.848 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.719 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.519 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.3 p80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 219' ' ' LEU . 3.6 tt -81.56 -29.0 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 133.92 -123.8 3.41 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.698 0.285 . . . . 0.0 110.858 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 61.11 30.91 19.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.79 0.329 . . . . 0.0 110.964 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -150.74 30.4 0.66 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.753 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -97.03 163.07 13.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 97.8 24.82 11.34 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.459 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.504 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 -101.59 21.84 13.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.572 ' O ' HD12 ' A' ' 271' ' ' LEU . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.823 0.345 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -155.64 178.37 10.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.79 153.76 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 2.5 mtpt -118.27 146.34 44.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.592 HG23 ' HA ' ' A' ' 229' ' ' ARG . 61.2 mt -63.16 144.61 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.025 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.524 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.856 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.403 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.524 HG22 ' HD3' ' A' ' 217' ' ' ARG . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.592 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.537 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.752 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.522 ' CE1' HG11 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.752 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.497 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.441 HD22 ' CD1' ' A' ' 250' ' ' LEU . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.441 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.522 HG11 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.856 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.856 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.759 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.53 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 2.2 p80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.485 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 274' ' ' PRO . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt -77.32 -29.41 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.4 -114.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.671 -0.775 . . . . 0.0 112.591 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.675 0.274 . . . . 0.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.5 -172.08 0.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -178.16 -39.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -140.98 162.44 35.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.23 -9.18 63.05 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.91 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.485 ' HB2' ' HD2' ' A' ' 277' ' ' LYS . 2.4 mt-10 -95.83 28.71 2.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.702 0.251 . . . . 0.0 110.974 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.587 ' O ' HD12 ' A' ' 271' ' ' LEU . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 62.47 -174.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 31.4 mt -120.32 145.83 46.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.85 140.77 36.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.435 HG23 ' HA ' ' A' ' 229' ' ' ARG . 44.4 mt -61.94 148.98 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.004 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.696 HG21 HG11 ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.887 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.456 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.457 ' HB2' HD22 ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.421 HG11 HD21 ' A' ' 231' ' ' LEU . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.595 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.567 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.654 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.567 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.468 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.595 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.566 HD22 ' CD1' ' A' ' 250' ' ' LEU . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.566 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.803 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.654 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.419 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.875 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.471 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.5 p80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.425 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.451 HD12 HD21 ' A' ' 219' ' ' LEU . 20.1 tt -88.73 -29.41 5.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -67.9 118.39 9.62 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.426 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 4.9 p90 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.621 0.248 . . . . 0.0 110.965 179.936 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.436 0 N-CA-C 112.579 -0.208 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -131.12 55.18 1.86 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.799 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -171.64 -41.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -125.58 162.44 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.845 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 102.19 -9.4 56.22 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.746 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 -95.45 30.89 2.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.667 0.234 . . . . 0.0 111.041 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.528 ' O ' HD12 ' A' ' 271' ' ' LEU . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.841 0.353 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.15 -58.72 3.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.792 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.678 HD22 HG11 ' A' ' 218' ' ' VAL . 44.3 mt -122.38 149.49 43.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.56 144.91 41.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.843 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt -65.24 141.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.081 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.531 ' HD3' HG22 ' A' ' 227' ' ' VAL . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.692 HG21 HG11 ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.791 HD21 HD12 ' A' ' 281' ' ' ILE . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.441 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.408 ' HA3' HG12 ' A' ' 244' ' ' VAL . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.531 HG22 ' HD3' ' A' ' 217' ' ' ARG . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 228' ' ' VAL . . . . . 0.433 HG13 ' SG ' ' A' ' 242' ' ' CYS . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.682 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 240' ' ' GLU . . . . . 0.404 ' OE1' HG21 ' A' ' 275' ' ' VAL . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.535 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.433 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.408 HG12 ' HA3' ' A' ' 226' ' ' GLY . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.603 HD22 ' CD1' ' A' ' 250' ' ' LEU . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.436 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.603 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.771 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.682 HG11 ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.401 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.897 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.721 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 275' ' ' VAL . . . . . 0.404 HG21 ' OE1' ' A' ' 240' ' ' GLU . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.422 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.462 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.791 HD12 HD21 ' A' ' 219' ' ' LEU . 11.5 tt -94.79 -29.71 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -156.46 141.38 7.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.622 0.249 . . . . 0.0 110.964 -179.926 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.549 -0.22 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -133.57 112.92 11.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.772 0.32 . . . . 0.0 110.959 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.81 175.72 9.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -137.89 162.71 33.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.7 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 66.28 25.75 72.46 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.475 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 -94.51 27.06 3.13 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.604 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.762 0.315 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -64.93 -31.82 73.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.933 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 46.2 mt -121.83 149.68 42.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.27 143.14 37.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.781 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 38.7 mt -64.53 148.74 11.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.929 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.55 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.705 HG21 HG11 ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.724 HD21 HD12 ' A' ' 281' ' ' ILE . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.475 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.603 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.432 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.432 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.475 ' SG ' HD23 ' A' ' 231' ' ' LEU . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.439 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.467 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.464 HD13 HD12 ' A' ' 250' ' ' LEU . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.464 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.8 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.603 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 261' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.424 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.424 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.88 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.76 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.489 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.7 p80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 281' ' ' ILE . . . . . 0.724 HD12 HD21 ' A' ' 219' ' ' LEU . 11.8 tt -96.8 -30.9 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -93.02 73.81 1.3 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.555 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.235 0 CA-C-O 120.669 0.271 . . . . 0.0 110.895 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.186 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -88.67 -75.5 0.43 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.881 0.372 . . . . 0.0 110.826 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -74.4 -35.74 63.47 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -98.04 162.59 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.788 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 112.85 2.7 25.29 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.752 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 -97.51 29.31 3.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.669 0.234 . . . . 0.0 110.948 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.584 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.757 0.313 . . . . 0.0 110.964 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -154.24 138.76 16.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.907 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 66.5 mt -107.31 142.15 37.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.855 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.76 146.64 50.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.669 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.5 mt -58.13 143.24 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.985 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.599 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.672 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.458 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.486 ' HG3' HD21 ' A' ' 271' ' ' LEU . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.599 HG22 ' HD3' ' A' ' 217' ' ' ARG . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.669 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.604 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.664 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.664 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.481 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.604 ' SG ' HD23 ' A' ' 231' ' ' LEU . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 244' ' ' VAL . . . . . 0.447 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.511 HD22 ' CD1' ' A' ' 250' ' ' LEU . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.511 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.759 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 266' ' ' GLN . . . . . 0.4 ' HG3' ' HD2' ' A' ' 267' ' ' PRO . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 267' ' ' PRO . . . . . 0.4 ' HD2' ' HG3' ' A' ' 266' ' ' GLN . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.861 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.716 ' O ' HG23 ' A' ' 278' ' ' VAL . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.424 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 274' ' ' PRO . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt -83.19 -28.52 7.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 98.71 -112.99 4.6 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.375 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 . . . . . 0 C--N 1.329 -0.326 0 CA-C-O 120.681 0.277 . . . . 0.0 110.869 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.542 -0.223 . . . . 0.0 112.542 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.36 106.97 12.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.904 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.92 74.26 1.05 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.755 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 -141.22 162.61 35.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.889 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 74.42 20.7 79.53 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.706 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.6 mt-10 -106.13 23.15 14.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.542 0.171 . . . . 0.0 111.038 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.649 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.848 0.356 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -153.55 162.94 40.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 212' ' ' LEU . . . . . 0.462 HD22 HG11 ' A' ' 218' ' ' VAL . 88.8 mt -112.57 147.56 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.934 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.96 148.5 52.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 214' ' ' ILE . . . . . 0.737 HG23 ' HA ' ' A' ' 229' ' ' ARG . 4.1 mt -59.38 138.92 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.891 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 217' ' ' ARG . . . . . 0.63 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 218' ' ' VAL . . . . . 0.721 HG21 HG11 ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.466 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 220' ' ' VAL . . . . . 0.89 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 224' ' ' LYS . . . . . 0.572 ' HE2' HD13 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 227' ' ' VAL . . . . . 0.63 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 229' ' ' ARG . . . . . 0.737 ' HA ' HG23 ' A' ' 214' ' ' ILE . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.542 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.608 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 236' ' ' PHE . . . . . 0.611 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 237' ' ' ALA . . . . . 0.608 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 242' ' ' CYS . . . . . 0.542 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 243' ' ' GLY . . . . . 0.452 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 246' ' ' LEU . . . . . 0.436 HD12 ' CA ' ' A' ' 251' ' ' GLY . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 248' ' ' GLU . . . . . 0.429 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 250' ' ' LEU . . . . . 0.572 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 251' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.611 HG11 ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 271' ' ' LEU . . . . . 0.874 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 273' ' ' ALA . . . . . 0.89 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 274' ' ' PRO . . . . . 0.726 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 276' ' ' HIS . . . . . 0.427 ' CE1' ' CB ' ' A' ' 274' ' ' PRO . 1.2 p80 -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 277' ' ' LYS . . . . . 0.454 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 278' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt -77.97 -27.48 14.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.38 26.68 8.56 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.59 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.628 0.251 . . . . 0.0 110.919 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.13 -62.46 0.06 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -101.01 28.77 5.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -141.22 162.66 34.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 70.28 18.12 74.77 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.783 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 449' ' ' GLU . . . . . 0.479 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -99.63 26.0 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 451' ' ' TYR . . . . . 0.619 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.637 HG23 ' HA ' ' A' ' 229' ' ' ARG . 7.2 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.909 0.385 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.58 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.661 HG21 HG11 ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.843 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.452 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.468 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.637 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.651 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.401 ' HB2' HG23 ' A' ' 234' ' ' THR . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.455 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.462 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.414 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.878 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.651 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.405 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 3.6 mm-40 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.878 HD13 ' HA2' ' A' ' 251' ' ' GLY . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.843 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.71 ' O ' HG23 ' A' ' 278' ' ' VAL . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.573 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.475 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.71 HG23 ' O ' ' A' ' 274' ' ' PRO . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.445 HD12 HD21 ' A' ' 219' ' ' LEU . 12.9 tt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.508 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 120.474 0.178 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.4 ' O ' HD12 ' A' ' 271' ' ' LEU . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.546 HG23 ' HA ' ' A' ' 229' ' ' ARG . 51.9 mt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.97 0.414 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.427 ' HD3' HG22 ' A' ' 227' ' ' VAL . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.427 HG22 ' HD3' ' A' ' 217' ' ' ARG . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.546 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.52 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.656 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.529 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.52 ' SG ' HD23 ' A' ' 231' ' ' LEU . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.464 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.401 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.482 HD22 ' CD1' ' A' ' 250' ' ' LEU . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.767 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.868 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.656 ' O ' HG23 ' A' ' 278' ' ' VAL . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.4 HD12 HD21 ' A' ' 219' ' ' LEU . 8.7 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.47 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.614 ' O ' HD12 ' A' ' 271' ' ' LEU . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.764 0.316 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.522 ' HG2' HG21 ' A' ' 281' ' ' ILE . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.701 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.854 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.438 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.4 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.654 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.61 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.654 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.428 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.4 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.454 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.434 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.484 HD22 ' CD1' ' A' ' 250' ' ' LEU . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.432 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.484 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.809 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.61 HG11 ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . 0.408 ' HB3' ' NH1' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.432 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.809 HD13 ' HA2' ' A' ' 251' ' ' GLY . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.854 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.697 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.559 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.701 HG11 HG21 ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.522 HG21 ' HG2' ' A' ' 217' ' ' ARG . 2.2 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.507 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 . . . . . 0 CA--C 1.523 -0.075 0 CA-C-O 120.387 0.137 . . . . 0.0 111.146 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.658 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.678 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.2 mt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.879 0.371 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.441 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.702 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.559 HD21 HD12 ' A' ' 281' ' ' ILE . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.877 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.441 HG22 ' HD3' ' A' ' 217' ' ' ARG . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.419 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.678 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.523 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.601 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.614 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.601 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.454 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.523 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.45 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 250' ' ' LEU . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.765 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.614 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.431 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.877 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.857 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.776 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.554 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 274' ' ' PRO . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.559 HD12 HD21 ' A' ' 219' ' ' LEU . 6.3 tt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.545 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.693 HD13 HG12 ' A' ' 228' ' ' VAL . 31.6 mm . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.795 0.331 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.439 ' HD3' HG22 ' A' ' 227' ' ' VAL . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.985 HD21 HD12 ' A' ' 281' ' ' ILE . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.565 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.439 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.693 HG12 HD13 ' A' ' 214' ' ' ILE . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.419 ' C ' HD12 ' A' ' 214' ' ' ILE . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . 0.435 ' N ' HD12 ' A' ' 214' ' ' ILE . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.553 HD12 HD11 ' A' ' 214' ' ' ILE . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.53 ' SG ' HD23 ' A' ' 231' ' ' LEU . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.481 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.407 HD12 ' CA ' ' A' ' 251' ' ' GLY . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.44 ' HB3' HD23 ' A' ' 250' ' ' LEU . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.565 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.713 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.402 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.852 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.718 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.5 p-80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.401 ' CD ' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 274' ' ' PRO . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.985 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.521 -0.138 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 229' ' ' ARG . 50.7 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.891 0.377 . . . . 0.0 110.979 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.697 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.892 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.45 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.697 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.407 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.489 ' HA ' HG23 ' A' ' 214' ' ' ILE . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.501 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.663 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.663 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.476 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.501 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.471 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.433 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.682 HD22 ' CD1' ' A' ' 250' ' ' LEU . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.682 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.769 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.632 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.892 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.862 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.701 ' O ' HG23 ' A' ' 278' ' ' VAL . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.54 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 274' ' ' PRO . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.404 HD12 HD21 ' A' ' 219' ' ' LEU . 10.9 tt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mm-40 . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.627 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.82 0.343 . . . . 0.0 110.977 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.457 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.706 HG21 HG11 ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.608 HD21 HD12 ' A' ' 281' ' ' ILE . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.899 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.452 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.446 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.457 HG22 ' HD3' ' A' ' 217' ' ' ARG . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.537 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.591 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.591 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.683 HD22 ' CD1' ' A' ' 250' ' ' LEU . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.683 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.784 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.889 HD23 ' HB ' ' A' ' 220' ' ' VAL . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.899 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.737 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.541 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.608 HD12 HD21 ' A' ' 219' ' ' LEU . 13.6 tt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 120.497 0.189 . . . . 0.0 111.027 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.566 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.731 0.301 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.696 ' HD3' HG22 ' A' ' 227' ' ' VAL . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.654 HG21 HG11 ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.616 HD21 HD12 ' A' ' 281' ' ' ILE . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.578 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.696 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.652 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.672 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.652 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.461 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.488 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.476 HD11 HD22 ' A' ' 271' ' ' LEU . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.463 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.578 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.776 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.672 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.436 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.436 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.845 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.722 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.549 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.616 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.516 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER . . . . . 0 C--O 1.227 -0.104 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.643 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.868 0.366 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.525 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.698 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.706 HD21 HD12 ' A' ' 281' ' ' ILE . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.874 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.58 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.494 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.625 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.69 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.625 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.471 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.494 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.46 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.438 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.422 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.58 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.685 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.69 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.874 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.694 ' O ' HG23 ' A' ' 278' ' ' VAL . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.564 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.458 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.698 HG11 HG21 ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.706 HD12 HD21 ' A' ' 219' ' ' LEU . 16.4 tt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.435 0.16 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.448 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.788 0.328 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.671 HG21 HG11 ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 281' ' ' ILE . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.458 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.446 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.535 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.607 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.535 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.493 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.446 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.427 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.637 HD22 ' CD1' ' A' ' 250' ' ' LEU . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.431 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.637 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.84 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.607 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.866 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.745 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.577 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.492 HD12 HD21 ' A' ' 219' ' ' LEU . 5.1 tt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.474 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.787 0.327 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.6 ' HD3' HG22 ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.44 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HA ' HD23 ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.6 HG22 ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.457 HG13 ' SG ' ' A' ' 242' ' ' CYS . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.487 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.457 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.507 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.436 HD21 HD22 ' A' ' 271' ' ' LEU . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 250' ' ' LEU . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.44 HD12 ' HD3' ' A' ' 224' ' ' LYS . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.788 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.86 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.555 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.449 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.419 HG21 ' CG ' ' A' ' 217' ' ' ARG . 16.3 tt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.518 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 . . . . . 0 CA--C 1.521 -0.157 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.415 HG23 ' HA ' ' A' ' 229' ' ' ARG . 31.5 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.761 0.315 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.613 ' HD3' HG22 ' A' ' 227' ' ' VAL . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.658 HG21 HG11 ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 281' ' ' ILE . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.531 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.45 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.613 HG22 ' HD3' ' A' ' 217' ' ' ARG . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.415 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.504 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.471 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.543 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.404 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.504 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.468 HD12 ' CA ' ' A' ' 251' ' ' GLY . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.468 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.531 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.697 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.471 HG11 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.453 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.853 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.725 ' O ' HG23 ' A' ' 278' ' ' VAL . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.555 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.467 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.518 HD12 HD21 ' A' ' 219' ' ' LEU . 6.5 tt . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.676 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.703 HG23 ' HA ' ' A' ' 229' ' ' ARG . 62.1 mt . . . . . 0 N--CA 1.456 -0.148 0 CA-C-O 120.816 0.341 . . . . 0.0 110.988 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.469 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.618 HG21 HG11 ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.638 HD21 HD12 ' A' ' 281' ' ' ILE . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.89 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.422 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.469 HG22 ' HD3' ' A' ' 217' ' ' ARG . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.448 HG13 ' SG ' ' A' ' 242' ' ' CYS . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.473 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.44 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.473 ' CG ' HG23 ' A' ' 234' ' ' THR . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.448 ' SG ' HG13 ' A' ' 228' ' ' VAL . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.456 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.547 HD13 HD12 ' A' ' 250' ' ' LEU . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.424 ' CB ' HD23 ' A' ' 250' ' ' LEU . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.547 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.758 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.89 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.792 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.47 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.47 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 274' ' ' PRO . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.618 HG11 HG21 ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.638 HD12 HD21 ' A' ' 219' ' ' LEU . 2.1 tt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.457 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 . . . . . 0 CA--C 1.521 -0.137 0 CA-C-O 120.387 0.137 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.582 ' O ' HD12 ' A' ' 271' ' ' LEU . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.476 HG23 ' HA ' ' A' ' 229' ' ' ARG . 48.6 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.864 0.364 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.567 ' HD3' HG22 ' A' ' 227' ' ' VAL . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.663 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 281' ' ' ILE . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.848 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.408 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.455 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.567 HG22 ' HD3' ' A' ' 217' ' ' ARG . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.476 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.522 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.57 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.522 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.446 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.562 HD22 ' CD1' ' A' ' 250' ' ' LEU . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.562 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.57 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.847 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.848 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.719 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.553 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 219' ' ' LEU . 3.6 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.504 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 . . . . . 0 CA--C 1.522 -0.112 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.572 ' O ' HD12 ' A' ' 271' ' ' LEU . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.592 HG23 ' HA ' ' A' ' 229' ' ' ARG . 61.2 mt . . . . . 0 CA--C 1.528 0.122 0 CA-C-O 120.78 0.324 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.524 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.856 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.403 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.524 HG22 ' HD3' ' A' ' 217' ' ' ARG . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.592 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.537 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.752 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.522 ' CE1' HG11 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.752 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.497 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.441 HD22 ' CD1' ' A' ' 250' ' ' LEU . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.441 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.522 HG11 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.856 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.856 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.759 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.559 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.485 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 274' ' ' PRO . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.485 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 . . . . . 0 N--CA 1.46 0.072 0 CA-C-O 120.451 0.167 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.587 ' O ' HD12 ' A' ' 271' ' ' LEU . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.435 HG23 ' HA ' ' A' ' 229' ' ' ARG . 44.4 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.898 0.38 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.696 HG21 HG11 ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.887 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.456 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.457 ' HB2' HD22 ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.421 HG11 HD21 ' A' ' 231' ' ' LEU . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.595 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.567 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.654 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.567 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.468 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.595 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.566 HD22 ' CD1' ' A' ' 250' ' ' LEU . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.566 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.803 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.654 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.419 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.875 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.556 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.425 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.451 HD12 HD21 ' A' ' 219' ' ' LEU . 20.1 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 . . . . . 0 CA--C 1.521 -0.155 0 CA-C-O 120.372 0.13 . . . . 0.0 111.041 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.528 ' O ' HD12 ' A' ' 271' ' ' LEU . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.853 0.359 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.531 ' HD3' HG22 ' A' ' 227' ' ' VAL . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.692 HG21 HG11 ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.791 HD21 HD12 ' A' ' 281' ' ' ILE . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.441 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.408 ' HA3' HG12 ' A' ' 244' ' ' VAL . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.531 HG22 ' HD3' ' A' ' 217' ' ' ARG . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . 0.433 HG13 ' SG ' ' A' ' 242' ' ' CYS . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.682 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . 0.404 ' OE1' HG21 ' A' ' 275' ' ' VAL . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.535 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.433 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.408 HG12 ' HA3' ' A' ' 226' ' ' GLY . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.603 HD22 ' CD1' ' A' ' 250' ' ' LEU . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.436 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.603 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.771 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.682 HG11 ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.401 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.897 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.721 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . 0.404 HG21 ' OE1' ' A' ' 240' ' ' GLU . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.462 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.791 HD12 HD21 ' A' ' 219' ' ' LEU . 11.5 tt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.475 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.604 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 38.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.92 0.391 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.55 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.705 HG21 HG11 ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.724 HD21 HD12 ' A' ' 281' ' ' ILE . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.475 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.603 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.432 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.432 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.475 ' SG ' HD23 ' A' ' 231' ' ' LEU . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.439 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.467 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.464 HD13 HD12 ' A' ' 250' ' ' LEU . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.464 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.8 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.603 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.424 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.424 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.88 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.76 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.534 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . 0.724 HD12 HD21 ' A' ' 219' ' ' LEU . 11.8 tt . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 . . . . . 0 CA--C 1.522 -0.124 0 CA-C-O 120.58 0.229 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.584 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.669 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.5 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.816 0.341 . . . . 0.0 110.985 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.599 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.672 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.458 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.486 ' HG3' HD21 ' A' ' 271' ' ' LEU . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.599 HG22 ' HD3' ' A' ' 217' ' ' ARG . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.669 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.604 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.664 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.664 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.481 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.604 ' SG ' HD23 ' A' ' 231' ' ' LEU . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . 0.447 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.511 HD22 ' CD1' ' A' ' 250' ' ' LEU . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.511 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.759 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 7.6 tp60 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . 0.4 ' HG3' ' HD2' ' A' ' 267' ' ' PRO . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . 0.4 ' HD2' ' HG3' ' A' ' 266' ' ' GLN . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.861 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.716 ' O ' HG23 ' A' ' 278' ' ' VAL . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.545 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 274' ' ' PRO . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.6 mt-10 . . . . . 0 CA--C 1.521 -0.136 0 CA-C-O 120.425 0.155 . . . . 0.0 111.038 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.649 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 214' ' ' ILE . . . . . 0.737 HG23 ' HA ' ' A' ' 229' ' ' ARG . 4.1 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.789 0.328 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 217' ' ' ARG . . . . . 0.63 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 218' ' ' VAL . . . . . 0.721 HG21 HG11 ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 219' ' ' LEU . . . . . 0.466 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 220' ' ' VAL . . . . . 0.89 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 224' ' ' LYS . . . . . 0.572 ' HE2' HD13 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 227' ' ' VAL . . . . . 0.63 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 229' ' ' ARG . . . . . 0.737 ' HA ' HG23 ' A' ' 214' ' ' ILE . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.542 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' THR . . . . . 0.608 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' PHE . . . . . 0.611 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' ALA . . . . . 0.608 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 242' ' ' CYS . . . . . 0.542 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 243' ' ' GLY . . . . . 0.452 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 246' ' ' LEU . . . . . 0.436 HD12 ' CA ' ' A' ' 251' ' ' GLY . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 248' ' ' GLU . . . . . 0.429 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' LEU . . . . . 0.572 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.611 HG11 ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' LEU . . . . . 0.874 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' ALA . . . . . 0.89 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' PRO . . . . . 0.726 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' HIS . . . . . 0.525 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' LYS . . . . . 0.454 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 449' ' ' GLU . . . . . 0.479 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER . . . . . 0 CA--C 1.523 -0.094 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 451' ' ' TYR . . . . . 0.619 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.3 mtt85 . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -71.17 -169.08 0.35 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.904 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.46 HD22 HG11 ' A' ' 218' ' ' VAL . 78.7 mt -104.36 150.77 24.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.24 144.82 50.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.637 HG23 ' HA ' ' A' ' 229' ' ' ARG . 7.2 mt -58.8 139.67 18.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.92 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.81 -1.55 83.57 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.665 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.17 144.98 25.03 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.903 0.382 . . . . 0.0 111.109 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.58 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.61 130.92 38.53 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.373 179.689 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.661 HG21 HG11 ' A' ' 278' ' ' VAL . 11.2 m -151.05 -176.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.064 0.459 . . . . 0.0 111.57 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 31.2 mt -123.79 121.56 35.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.252 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.843 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.87 112.4 24.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.92 0.391 . . . . 0.0 110.123 179.528 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.44 82.76 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.308 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -26.29 10.57 Favored Glycine 0 C--N 1.333 0.4 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.774 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 27.2 p -100.18 -27.79 13.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.801 0.334 . . . . 0.0 110.972 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -99.83 148.98 23.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.703 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.452 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.53 143.54 47.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.045 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.12 -169.23 35.37 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.787 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.7 t -118.66 132.96 67.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 0.0 110.924 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.468 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.1 t -61.39 133.55 27.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.564 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.637 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.07 -40.29 2.62 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.339 -179.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -149.02 150.21 32.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.018 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.9 OUTLIER -134.02 125.65 28.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.911 0.386 . . . . 0.0 110.986 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.07 -173.64 42.32 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.387 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -79.9 159.76 26.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.752 0.31 . . . . 0.0 110.865 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 43.0 p -106.53 159.76 15.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.79 -2.89 58.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.405 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.651 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -123.32 -17.12 6.67 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.719 -0.219 . . . . 0.0 111.467 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.41 144.96 47.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.866 0.365 . . . . 0.0 111.223 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ttmt -90.94 136.88 32.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.874 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.95 -164.14 12.54 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.64 135.24 39.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.401 ' HB2' HG23 ' A' ' 234' ' ' THR . 58.0 m95 -132.48 168.16 18.69 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -137.9 156.11 48.23 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.03 0.443 . . . . 0.0 111.062 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.455 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.37 126.52 7.46 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.06 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.462 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.28 131.5 67.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.82 0.343 . . . . 0.0 111.157 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 47.0 tt0 -84.69 111.98 20.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.038 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.414 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 27.4 mt -67.83 144.12 55.47 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.016 0.436 . . . . 0.0 111.496 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -68.96 -24.04 64.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.07 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 3.4 mt-10 -138.08 168.54 15.73 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.773 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.477 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -65.8 69.93 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.485 2.123 . . . . 0.0 112.256 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.64 27.82 6.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.127 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.878 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.06 -170.83 20.03 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.445 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 37.0 mmtt -116.22 -34.2 4.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.669 0.271 . . . . 0.0 111.055 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.41 167.5 12.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.929 0.395 . . . . 0.0 111.071 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -99.18 25.64 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.112 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.24 17.18 14.37 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.938 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.15 159.15 42.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.788 0.328 . . . . 0.0 111.239 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.651 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.2 t -147.2 121.63 2.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.206 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.96 35.17 26.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.338 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 82.11 10.76 83.4 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.707 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.8 m -116.96 113.9 23.05 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.734 0.302 . . . . 0.0 110.771 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 7.6 tmm_? -88.72 113.42 24.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -86.04 -33.94 20.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.496 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.0 p90 -154.21 169.82 22.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.657 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.81 127.09 52.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.999 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.0 p -154.18 162.42 41.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.405 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 3.6 mm-40 -60.87 165.41 6.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.857 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -63.79 136.57 54.07 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.656 2.237 . . . . 0.0 112.171 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt 61.28 19.92 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.396 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.477 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.1 m-85 -110.69 -9.5 14.51 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.584 -0.28 . . . . 0.0 111.139 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -89.88 120.22 5.75 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.774 -179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.878 HD13 ' HA2' ' A' ' 251' ' ' GLY . 8.2 tp -128.81 125.92 38.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.775 0.322 . . . . 0.0 110.539 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.496 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -103.91 112.68 25.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.421 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.843 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.47 149.02 58.7 Favored Pre-proline 0 C--O 1.232 0.162 0 CA-C-O 120.909 0.385 . . . . 0.0 111.077 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.71 ' O ' HG23 ' A' ' 278' ' ' VAL . 58.0 Cg_exo -50.4 162.83 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.961 2.441 . . . . 0.0 112.631 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.8 p -71.22 -32.18 46.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.062 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.573 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -75.63 -27.58 58.48 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.847 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.475 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.12 -19.6 53.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.71 HG23 ' O ' ' A' ' 274' ' ' PRO . 22.4 t -96.87 143.18 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.46 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.18 147.75 35.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.717 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.7 130.68 42.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.834 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.445 HD12 HD21 ' A' ' 219' ' ' LEU . 12.9 tt -80.91 -30.07 11.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.69 80.42 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.463 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 C--N 1.328 -0.369 0 CA-C-O 120.703 0.287 . . . . 0.0 110.862 -179.906 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -99.52 35.87 1.88 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.862 0.363 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 63.52 140.42 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 34.2 mm-40 -140.99 162.65 34.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.82 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.39 17.9 44.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.668 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.508 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.7 mm-40 -106.12 25.34 11.11 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 122.894 -0.18 . . . . 0.0 110.96 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 3.6 pm0 -139.36 152.96 47.57 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.927 0.394 . . . . 0.0 111.329 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.4 ' O ' HD12 ' A' ' 271' ' ' LEU . 44.2 m-85 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.999 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.751 0.31 . . . . 0.0 110.918 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -59.44 -77.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 218' ' ' VAL . 78.2 mt -114.49 146.3 40.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -132.38 148.15 52.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.696 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.546 HG23 ' HA ' ' A' ' 229' ' ' ARG . 51.9 mt -60.06 135.45 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.899 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.79 -2.58 73.03 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -94.11 143.62 26.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.829 0.347 . . . . 0.0 111.033 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.427 ' HD3' HG22 ' A' ' 227' ' ' VAL . 3.6 tpp180 -76.73 129.99 37.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.425 179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 278' ' ' VAL . 10.6 m -148.89 -175.85 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.594 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 37.9 mt -124.34 121.28 34.55 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.115 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.61 111.6 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.007 0.432 . . . . 0.0 110.17 179.6 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.68 -6.51 82.48 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.467 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -26.69 9.94 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.637 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.1 p -99.26 -27.91 13.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.908 0.385 . . . . 0.0 111.0 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.2 mmpt? -99.84 147.75 25.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.737 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.32 145.1 47.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.063 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.49 -166.86 33.73 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.734 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.427 HG22 ' HD3' ' A' ' 217' ' ' ARG . 73.1 t -121.32 133.37 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.5 t -60.4 131.51 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.647 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.546 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.2 mmt180 -120.05 -37.31 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.335 -179.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 28.7 t80 -152.49 149.27 28.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.77 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.52 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.77 124.69 27.04 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.912 0.387 . . . . 0.0 111.013 179.865 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 170.01 -174.99 44.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.524 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.83 159.42 26.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.815 0.341 . . . . 0.0 110.834 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.656 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -106.8 162.78 13.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.91 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -87.43 -5.21 58.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.5 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.86 -16.9 7.5 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.58 0.229 . . . . 0.0 111.427 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.44 140.21 51.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.919 0.39 . . . . 0.0 111.12 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -84.67 144.81 28.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 98.99 -167.66 21.86 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.493 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -96.32 135.04 38.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.793 0.33 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.529 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.2 m95 -129.11 168.18 16.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.96 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.52 ' SG ' HD23 ' A' ' 231' ' ' LEU . 32.6 t -134.36 155.77 49.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.041 0.448 . . . . 0.0 111.07 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.464 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.17 126.32 7.13 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.128 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.401 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 133.05 66.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.856 0.36 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -84.39 110.96 19.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.983 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.482 HD22 ' CD1' ' A' ' 250' ' ' LEU . 77.9 mt -67.73 145.0 55.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.086 0.47 . . . . 0.0 111.562 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -71.79 -24.03 61.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.156 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.427 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 5.8 mt-10 -137.66 168.77 15.05 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.956 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.456 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.59 69.18 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.559 2.173 . . . . 0.0 112.14 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.57 24.48 6.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.028 179.996 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.767 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.59 178.29 21.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.613 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 48.7 mmtt -111.64 -27.48 8.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 111.011 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -117.89 159.83 22.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.128 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -101.27 25.48 8.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.48 3.16 40.82 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.98 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -132.02 159.0 40.07 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.808 0.337 . . . . 0.0 111.272 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.9 t -144.93 121.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.045 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.37 26.8 14.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.19 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.07 63.45 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.768 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 13.0 m -117.28 115.82 26.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.754 0.312 . . . . 0.0 110.939 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 14.9 ttm105 -89.36 111.39 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.689 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -83.57 -33.53 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.835 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.509 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 11.9 p90 -155.12 175.34 13.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.704 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -104.76 128.93 53.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.896 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 30.8 p -154.18 158.01 39.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -60.91 165.15 6.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.3 133.48 40.66 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.205 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER 59.37 23.53 12.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.12 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.456 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.7 m-85 -112.05 -17.83 12.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.088 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.86 134.55 13.75 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.67 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.8 tp -138.11 125.9 22.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.725 0.298 . . . . 0.0 110.62 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.509 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.3 m-85 -105.12 112.76 26.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.252 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.868 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.26 148.64 52.05 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-O 120.896 0.379 . . . . 0.0 111.116 179.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.656 ' O ' HG23 ' A' ' 278' ' ' VAL . 75.6 Cg_exo -48.31 162.51 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.969 2.446 . . . . 0.0 112.75 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -70.38 -33.57 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.868 179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -76.96 -24.97 52.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.82 -20.11 53.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 110.857 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 218' ' ' VAL . 18.6 t -96.92 143.84 11.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.262 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.22 141.62 32.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.858 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.29 128.79 37.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.823 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.4 HD12 HD21 ' A' ' 219' ' ' LEU . 8.7 tt -72.58 -23.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.16 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -130.29 53.89 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.4 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 5.5 t80 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.64 0.257 . . . . 0.0 110.843 -179.889 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -155.09 -48.39 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.796 0.331 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 12.8 mp0 -133.58 31.82 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.809 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -113.88 162.73 16.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.864 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 92.14 16.41 50.65 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.639 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.47 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.3 mt-10 -106.18 29.49 6.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.524 0.202 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -141.99 154.63 45.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.983 0.421 . . . . 0.0 111.205 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.614 ' O ' HD12 ' A' ' 271' ' ' LEU . 48.3 m-85 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.9 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.79 0.328 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -78.54 155.32 29.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 36.3 mt -121.94 151.73 40.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.793 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.03 141.59 42.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.945 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.3 mt -63.28 142.69 16.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.141 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.68 -0.41 84.76 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.731 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.07 146.4 23.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.522 ' HG2' HG21 ' A' ' 281' ' ' ILE . 7.5 tpp180 -76.61 135.07 39.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.444 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.701 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.97 -175.68 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.119 0.485 . . . . 0.0 111.57 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . 43.9 mt -124.22 121.42 35.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.854 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -87.61 111.38 21.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.0 0.429 . . . . 0.0 110.099 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.53 82.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.518 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.63 -26.56 10.38 Favored Glycine 0 C--N 1.333 0.364 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.718 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 37.1 p -99.26 -28.22 13.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.819 0.343 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.438 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.9 OUTLIER -99.83 147.9 25.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.711 -179.894 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.22 147.77 43.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -178.63 -169.37 39.24 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.587 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.88 134.9 61.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.4 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.5 t -62.68 125.78 19.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.505 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.3 mmm180 -113.04 -30.05 7.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.415 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -161.49 152.0 17.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.784 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -134.17 127.56 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.881 0.372 . . . . 0.0 110.931 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.0 -174.24 42.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.517 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.83 166.98 21.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.765 0.317 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.654 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.6 p -113.51 163.39 14.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -86.8 -5.97 58.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.283 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.61 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -120.69 -17.07 8.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.608 0.242 . . . . 0.0 111.377 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.654 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.35 141.68 49.84 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.787 0.327 . . . . 0.0 111.2 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -90.83 137.35 32.43 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.832 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.91 -162.69 12.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.446 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -99.72 132.58 44.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.924 0.392 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.428 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.0 m95 -129.96 169.05 15.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.4 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.3 t -136.88 155.87 49.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.045 0.45 . . . . 0.0 111.105 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.454 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.25 125.92 7.07 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.224 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.434 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.08 132.36 67.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.791 0.329 . . . . 0.0 111.054 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -84.37 111.37 19.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.484 HD22 ' CD1' ' A' ' 250' ' ' LEU . 95.4 mt -67.74 147.8 52.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.121 0.486 . . . . 0.0 111.45 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -74.08 -27.87 61.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.204 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.432 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.5 OUTLIER -133.33 170.26 11.82 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.904 -179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -66.74 68.71 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.907 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.484 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.39 27.0 6.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.261 -179.931 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.809 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.89 -171.4 20.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.469 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 14.5 mmtt -115.2 -32.32 5.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.659 0.266 . . . . 0.0 111.219 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -125.04 167.14 15.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 111.143 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -98.19 25.91 5.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.048 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.25 17.69 11.23 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.874 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.14 159.09 42.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.878 0.37 . . . . 0.0 111.247 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.61 HG11 ' CD1' ' A' ' 236' ' ' PHE . 48.9 t -142.16 120.22 8.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.47 27.63 12.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.384 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.85 4.8 64.93 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.827 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 24.1 m -112.3 113.93 26.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.87 0.367 . . . . 0.0 110.767 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . 0.408 ' HB3' ' NH1' ' A' ' 261' ' ' ARG . 6.9 ttp-105 -86.81 122.07 30.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.838 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 -95.49 -38.32 10.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.822 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.493 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.5 p90 -148.35 171.31 16.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.797 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 38.9 tp60 -104.85 129.13 53.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.29 161.97 41.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 -60.9 165.18 6.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.62 128.57 26.26 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.434 2.089 . . . . 0.0 112.192 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 19.1 mmtp 63.3 20.94 12.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.249 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.432 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.1 m-85 -111.75 21.0 16.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.997 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.76 123.96 5.39 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.658 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.809 HD13 ' HA2' ' A' ' 251' ' ' GLY . 10.2 tp -130.42 125.75 35.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.811 0.339 . . . . 0.0 110.668 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.493 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -99.36 112.4 24.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.118 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.854 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.14 149.94 62.93 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.849 0.357 . . . . 0.0 111.202 179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.697 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.5 Cg_exo -51.56 162.66 1.44 Allowed 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.926 2.417 . . . . 0.0 112.675 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.9 -31.79 46.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.879 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.559 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -76.02 -25.8 56.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.916 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.2 OUTLIER -80.03 -19.79 46.84 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.778 179.671 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.701 HG11 HG21 ' A' ' 218' ' ' VAL . 16.8 t -97.64 140.84 16.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.33 142.05 37.66 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.912 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.04 127.4 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.736 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.522 HG21 ' HG2' ' A' ' 217' ' ' ARG . 2.2 tt -68.75 -25.56 30.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.195 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -58.55 -165.99 0.12 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.481 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 10.6 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.604 0.24 . . . . 0.0 110.865 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.37 73.57 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.912 0.386 . . . . 0.0 110.889 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -99.33 83.66 2.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -139.53 162.46 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.83 -8.17 61.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.823 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.507 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 -94.04 20.75 7.49 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 122.855 -0.203 . . . . 0.0 111.146 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.0 OUTLIER -134.46 153.29 52.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.915 0.388 . . . . 0.0 111.348 -179.766 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.658 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.2 m-85 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.332 -0.842 . . . . 0.0 110.956 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.869 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -136.16 169.35 17.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.558 HD22 HG11 ' A' ' 218' ' ' VAL . 76.2 mt -114.61 157.91 22.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.47 145.35 45.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.678 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.2 mt -58.17 137.63 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.059 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 92.93 -6.46 76.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.635 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -94.08 142.73 27.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.932 0.396 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.441 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.6 tpp180 -76.72 135.16 39.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.521 179.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.702 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -153.71 -175.85 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.475 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.559 HD21 HD12 ' A' ' 281' ' ' ILE . 41.1 mt -124.25 121.5 35.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.197 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.877 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.53 112.03 23.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.142 179.478 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.77 -6.44 82.81 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.487 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.29 -25.92 11.48 Favored Glycine 0 C--N 1.334 0.42 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.793 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.8 p -100.12 -27.59 13.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.781 0.324 . . . . 0.0 110.962 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.462 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -99.9 147.22 25.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.616 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.9 143.44 47.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.417 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.59 -166.32 31.69 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.832 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.441 HG22 ' HD3' ' A' ' 217' ' ' ARG . 72.0 t -121.2 133.09 68.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.746 0.307 . . . . 0.0 110.923 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.419 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.2 t -60.6 128.8 22.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.661 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.678 ' HA ' HG23 ' A' ' 214' ' ' ILE . 5.1 mmt180 -117.4 -29.83 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.503 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -161.54 149.33 15.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.653 0.263 . . . . 0.0 110.832 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.523 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -133.9 128.28 34.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.835 0.35 . . . . 0.0 111.072 179.873 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.73 -173.8 42.1 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.483 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -79.75 165.11 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.601 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.4 p -113.26 166.03 11.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.941 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.52 -5.27 56.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.188 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.614 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.43 -17.07 8.26 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 116.702 -0.226 . . . . 0.0 111.262 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.601 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 140.49 51.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.785 0.326 . . . . 0.0 111.196 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.3 pttp -91.01 125.66 35.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 121.72 -163.13 15.24 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.508 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -97.23 134.16 40.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.454 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.6 m95 -133.03 165.06 25.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.946 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.523 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.2 t -134.51 155.67 49.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.022 0.439 . . . . 0.0 111.064 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.45 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.29 125.96 7.09 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.184 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.35 132.02 66.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.811 0.339 . . . . 0.0 111.19 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.417 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.2 tt0 -84.48 111.94 19.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 250' ' ' LEU . 62.9 mt -67.31 152.77 45.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.13 0.49 . . . . 0.0 111.593 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -76.5 -29.19 56.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.104 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -134.16 170.47 11.21 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -65.15 69.6 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.625 2.216 . . . . 0.0 112.166 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.54 21.95 7.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.204 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.765 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.36 -171.28 23.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.507 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -116.66 -35.77 4.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.722 0.296 . . . . 0.0 111.278 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -120.02 164.43 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.111 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 18.7 p-10 -96.95 25.53 5.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.042 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.89 18.3 10.8 Favored Glycine 0 C--N 1.329 0.181 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.78 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.24 158.92 43.34 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.898 0.38 . . . . 0.0 111.243 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.614 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.5 t -141.85 116.92 5.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.092 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.09 13.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.305 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.22 -3.15 61.66 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.808 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 23.9 m -103.92 114.43 28.67 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.734 0.302 . . . . 0.0 110.887 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 25.3 ttm105 -88.59 120.67 30.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.91 -42.72 8.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.499 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.4 p90 -144.01 173.02 12.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.758 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 15.1 tp60 -104.76 126.45 51.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.831 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 17.1 p -154.13 158.43 40.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.431 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 6.0 mt-30 -60.8 165.69 5.55 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -63.48 135.46 49.72 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.619 2.212 . . . . 0.0 112.094 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.3 mmmt 62.88 20.07 11.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.457 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -110.69 -19.2 12.95 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.73 0.3 . . . . 0.0 111.067 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.07 118.63 4.75 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.772 -179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.877 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.33 125.99 43.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 0.0 110.445 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.499 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -105.47 112.95 26.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.444 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.857 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.21 148.75 49.28 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.885 0.374 . . . . 0.0 111.125 179.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.776 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.9 Cg_exo -49.11 162.61 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.047 2.498 . . . . 0.0 112.715 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.51 -31.86 44.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.876 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.554 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.6 p-80 -76.9 -26.45 54.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.795 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' B' ' 449' ' ' GLU . 1.0 OUTLIER -77.84 -19.97 53.94 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.736 179.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 274' ' ' PRO . 14.4 t -94.75 140.98 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.33 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.837 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.19 133.98 55.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.692 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.559 HD12 HD21 ' A' ' 219' ' ' LEU . 6.3 tt -91.21 -29.0 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.107 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 125.8 -156.16 19.36 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.3 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 120.634 0.254 . . . . 0.0 110.844 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -118.83 100.89 7.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.372 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.34 -35.24 5.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.865 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -126.56 162.83 24.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 100.22 21.52 13.24 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.488 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.4 mm-40 -106.2 27.03 9.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.53 0.205 . . . . 0.0 111.059 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 4.2 pm0 -137.47 150.09 47.32 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.83 0.348 . . . . 0.0 111.388 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.545 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.6 m-85 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.915 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . 0.559 HH12 HG23 ' A' ' 279' ' ' THR . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.091 0 CA-C-O 120.841 0.353 . . . . 0.0 110.726 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.6 78.7 1.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 63.2 mt -110.23 147.3 34.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.902 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.31 147.02 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.774 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.693 HD13 HG12 ' A' ' 228' ' ' VAL . 31.6 mm -59.45 139.48 19.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.076 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.93 -2.74 82.29 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.785 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.24 145.54 24.65 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.798 0.332 . . . . 0.0 111.188 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.439 ' HD3' HG22 ' A' ' 227' ' ' VAL . 4.9 tpp85 -76.69 133.0 39.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.499 179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 278' ' ' VAL . 9.6 m -151.68 -175.67 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.996 0.427 . . . . 0.0 111.583 -179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.985 HD21 HD12 ' A' ' 281' ' ' ILE . 39.8 mt -124.38 121.43 34.91 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.241 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.88 111.08 21.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.874 0.368 . . . . 0.0 110.269 179.51 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.23 -6.4 83.42 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.522 -179.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.67 -26.22 11.34 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.693 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.3 p -100.39 -27.11 13.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 110.986 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.565 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.81 147.65 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.6 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.67 143.0 48.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.181 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.72 -167.42 33.37 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.774 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.439 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.0 t -119.2 133.15 66.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.04 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.693 HG12 HD13 ' A' ' 214' ' ' ILE . 34.7 t -60.45 124.24 14.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.419 ' C ' HD12 ' A' ' 214' ' ' ILE . 6.2 mmt180 -114.57 -23.42 9.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.676 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . 0.435 ' N ' HD12 ' A' ' 214' ' ' ILE . 15.1 t80 -168.01 151.57 5.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.644 0.259 . . . . 0.0 110.963 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.553 HD12 HD11 ' A' ' 214' ' ' ILE . 0.8 OUTLIER -134.32 123.9 24.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.731 0.3 . . . . 0.0 111.014 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.19 -177.95 44.6 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.549 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -79.88 158.78 26.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 25.6 p -105.5 159.56 15.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.81 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -85.09 -0.27 53.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.465 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.649 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.04 -16.95 6.39 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.583 0.23 . . . . 0.0 111.48 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.26 140.44 51.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.829 0.347 . . . . 0.0 111.307 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.91 131.7 34.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 113.04 -167.31 12.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.554 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -95.1 136.76 35.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 53.6 m95 -132.97 168.62 18.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.53 ' SG ' HD23 ' A' ' 231' ' ' LEU . 34.8 t -135.61 156.03 49.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.98 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.81 125.8 6.94 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.21 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.481 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.6 t -129.15 132.64 66.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.771 0.32 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.41 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 48.2 tt0 -84.57 110.88 19.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.975 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.407 HD12 ' CA ' ' A' ' 251' ' ' GLY . 94.3 mt -67.35 140.26 57.23 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.443 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -68.83 -24.37 64.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.33 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.44 ' HB3' HD23 ' A' ' 250' ' ' LEU . 3.5 mt-10 -137.17 169.26 13.7 Favored Pre-proline 0 C--N 1.331 -0.207 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.911 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.476 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.8 Cg_endo -66.45 68.11 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.576 2.184 . . . . 0.0 112.3 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.565 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.28 28.22 6.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.945 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.713 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.79 -159.82 16.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.478 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 40.1 mmtt -125.98 -41.47 1.95 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.743 0.306 . . . . 0.0 111.219 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -116.43 170.27 8.68 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.054 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 19.4 p-10 -99.9 25.86 6.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.002 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.09 18.22 11.66 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.94 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.83 152.9 49.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.872 0.368 . . . . 0.0 111.22 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.649 HG11 ' CD1' ' A' ' 236' ' ' PHE . 44.5 t -135.39 116.26 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.042 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.63 24.02 11.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.33 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 98.17 10.62 51.22 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.769 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.7 m -117.17 113.94 22.96 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.738 0.304 . . . . 0.0 110.875 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 61.9 ttp85 -88.71 109.9 20.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.931 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -83.07 -34.87 26.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.799 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.0 p90 -151.65 173.62 14.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.696 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -104.73 128.67 52.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.033 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 21.8 p -154.23 161.5 41.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.402 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 19.3 mm-40 -60.85 165.67 5.64 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.58 131.27 32.9 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.577 2.185 . . . . 0.0 112.052 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 8.9 mttp 60.87 24.5 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.252 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.476 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.8 m-85 -111.31 -19.21 12.72 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.038 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.37 126.01 7.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.784 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.6 tp -130.66 131.82 45.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.639 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.8 m-85 -109.53 112.6 24.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.263 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.852 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.08 149.71 59.41 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.9 0.381 . . . . 0.0 111.069 179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.718 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.0 Cg_exo -49.02 162.62 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.922 2.414 . . . . 0.0 112.696 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 210' ' ' ARG . 9.4 p -71.75 -31.26 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.817 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.5 p-80 -77.77 -25.95 49.47 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.919 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.401 ' CD ' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.94 -19.82 53.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.712 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 274' ' ' PRO . 16.1 t -95.91 144.76 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.369 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . 0.559 HG23 HH12 ' A' ' 210' ' ' ARG . 0.3 OUTLIER -142.5 143.53 32.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.753 179.983 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.24 131.68 50.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.847 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.985 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt -96.96 -25.09 4.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.283 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -53.97 130.25 43.35 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.626 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.6 t80 . . . . . 0 C--N 1.327 -0.371 0 CA-C-O 120.674 0.273 . . . . 0.0 110.453 179.819 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -72.93 80.32 1.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.768 0.318 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 61.43 -177.63 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -132.92 162.77 30.73 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 91.53 22.34 31.8 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.567 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -106.01 26.72 9.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.52 0.2 . . . . 0.0 110.966 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.7 OUTLIER -142.03 152.02 42.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.916 0.388 . . . . 0.0 111.327 -179.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.0 m-85 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.901 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.813 0.339 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.86 145.27 24.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.781 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.441 HD11 ' HB ' ' A' ' 278' ' ' VAL . 83.9 mt -115.03 150.45 35.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.03 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.09 145.94 48.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 229' ' ' ARG . 50.7 mt -61.94 146.31 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.979 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.25 -0.56 87.42 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.709 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.19 144.87 25.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.866 0.365 . . . . 0.0 111.044 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.697 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.1 OUTLIER -76.75 133.28 39.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.453 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 278' ' ' VAL . 10.3 m -153.03 -175.94 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.914 0.388 . . . . 0.0 111.569 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.0 mt -124.35 121.32 34.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.244 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.892 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.35 112.1 23.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.943 0.402 . . . . 0.0 110.123 179.447 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.48 -6.44 82.21 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.515 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.07 -25.59 11.81 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.766 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.2 p -99.81 -28.33 13.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 0.0 110.836 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.45 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.0 OUTLIER -99.9 147.16 25.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.766 -179.836 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.449 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.11 142.44 47.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.036 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -172.15 -167.67 32.56 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.915 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.697 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.7 t -119.58 132.15 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.716 0.293 . . . . 0.0 111.047 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.407 HG13 ' SG ' ' A' ' 242' ' ' CYS . 25.9 t -60.26 133.59 25.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.538 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.489 ' HA ' HG23 ' A' ' 214' ' ' ILE . 3.1 mmt180 -121.07 -44.95 2.38 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.376 -179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -145.75 144.93 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.695 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.501 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -129.89 122.22 28.19 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.904 0.383 . . . . 0.0 111.062 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 171.32 -171.63 44.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.377 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -80.0 159.99 26.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.905 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.663 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.9 p -107.94 160.32 15.86 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -84.95 -4.08 58.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.407 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.91 -17.0 7.45 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.554 0.216 . . . . 0.0 111.453 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.663 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.45 141.22 50.36 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.814 0.34 . . . . 0.0 111.344 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.54 130.38 35.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 115.7 -165.42 12.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.524 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -95.54 134.32 38.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.753 0.311 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.476 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.6 m95 -132.71 167.31 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.972 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.501 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.1 t -135.57 155.78 49.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.024 0.44 . . . . 0.0 111.077 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.471 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.55 126.41 7.25 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.705 -0.679 . . . . 0.0 112.157 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.433 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.28 131.38 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.811 0.338 . . . . 0.0 111.245 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.411 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 14.8 tt0 -84.46 111.78 19.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.898 179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.682 HD22 ' CD1' ' A' ' 250' ' ' LEU . 37.2 mt -67.32 155.32 39.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.049 0.452 . . . . 0.0 111.532 -178.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -78.61 -27.63 45.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.116 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -135.03 170.66 10.62 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.758 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.401 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -65.07 69.5 0.27 Allowed 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.564 2.176 . . . . 0.0 112.097 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.682 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.4 25.42 6.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.274 -179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.769 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.32 -173.1 20.93 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -115.27 -31.24 6.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.696 0.284 . . . . 0.0 111.289 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -123.25 165.69 16.52 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.98 0.419 . . . . 0.0 111.009 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -97.47 25.67 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.03 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.49 14.21 20.51 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.826 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.26 158.99 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.632 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.5 t -142.47 122.47 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.68 26.57 11.43 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.347 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.96 11.47 60.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.645 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 2.5 m -117.32 113.95 22.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.879 0.371 . . . . 0.0 110.665 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -87.59 113.19 23.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.831 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -87.55 -31.11 20.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.791 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.5 p90 -157.07 174.31 15.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.893 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -104.81 126.26 51.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.838 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 28.9 p -154.16 158.09 39.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.974 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 29.0 mt-30 -60.85 165.74 5.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.021 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.47 136.12 53.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.574 2.183 . . . . 0.0 112.051 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 20.7 mmtt 61.64 19.05 10.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.337 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -109.1 -19.11 13.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 110.986 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -78.47 119.39 5.12 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.722 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.892 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -128.37 126.54 40.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.85 0.357 . . . . 0.0 110.419 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.2 m-85 -105.99 112.78 25.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.47 -179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.862 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.8 148.45 52.7 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.069 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.701 ' O ' HG23 ' A' ' 278' ' ' VAL . 71.7 Cg_exo -47.95 162.44 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.985 2.457 . . . . 0.0 112.818 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.9 p -69.85 -36.37 69.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.969 179.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.54 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -75.3 -24.8 57.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.884 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.24 -20.17 52.27 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.763 0.316 . . . . 0.0 110.743 179.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 274' ' ' PRO . 26.4 t -94.36 140.07 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.153 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.93 137.62 45.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.944 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.82 133.04 50.14 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.767 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.404 HD12 HD21 ' A' ' 219' ' ' LEU . 10.9 tt -82.72 -28.75 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.073 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 172.83 -124.17 1.05 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.452 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.617 0.246 . . . . 0.0 110.804 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 61.13 161.12 0.06 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.74 0.305 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -96.47 20.94 9.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.059 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -141.3 162.73 34.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.776 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 78.53 21.2 69.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.615 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mm-40 -105.33 24.61 11.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.522 0.201 . . . . 0.0 110.879 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.8 pm0 -139.6 154.27 47.56 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.955 0.407 . . . . 0.0 111.205 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.627 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.312 -0.852 . . . . 0.0 110.889 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.778 0.323 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -58.88 161.82 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.894 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 74.0 mt -120.54 158.04 28.15 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.001 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.01 146.2 48.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.792 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 35.3 mt -64.08 140.12 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.977 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.3 -0.98 84.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.769 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -94.14 146.14 24.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.457 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.5 tpp85 -76.38 129.71 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.302 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.706 HG21 HG11 ' A' ' 278' ' ' VAL . 11.3 m -147.75 -175.9 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.078 0.466 . . . . 0.0 111.667 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.608 HD21 HD12 ' A' ' 281' ' ' ILE . 36.7 mt -124.67 121.64 35.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.299 178.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.899 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.4 111.77 23.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.912 0.387 . . . . 0.0 110.073 179.568 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.67 -6.62 82.21 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.557 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.4 10.67 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.69 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 29.4 p -100.06 -27.12 13.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.742 0.306 . . . . 0.0 110.738 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.452 ' HG3' HD21 ' A' ' 271' ' ' LEU . 1.0 OUTLIER -100.0 146.72 26.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.698 -179.84 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.446 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.3 143.92 48.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.122 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.13 -169.15 36.63 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.537 -0.839 . . . . 0.0 112.639 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.457 HG22 ' HD3' ' A' ' 217' ' ' ARG . 78.2 t -117.34 135.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.826 0.346 . . . . 0.0 110.979 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.537 HG13 ' SG ' ' A' ' 242' ' ' CYS . 22.0 t -63.95 129.84 28.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.696 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -117.67 -40.59 3.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.2 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -146.31 150.89 36.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.061 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mt -134.59 119.88 18.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.932 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.26 -174.13 45.4 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.588 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -79.72 162.8 24.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.591 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 28.6 p -109.74 163.08 13.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.997 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.57 -2.75 58.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.4 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.21 -17.04 7.28 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-O 120.498 0.189 . . . . 0.0 111.449 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.591 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.31 141.25 50.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.68 0.276 . . . . 0.0 111.311 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 23.2 mtmm -90.89 121.35 32.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.95 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 126.43 -165.03 19.8 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.569 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -95.05 134.4 37.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.836 0.351 . . . . 0.0 110.862 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.484 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 60.1 m95 -134.35 169.21 17.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.922 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 228' ' ' VAL . 43.8 t -140.23 155.69 46.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.087 0.47 . . . . 0.0 111.13 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -112.24 126.25 7.51 Favored Glycine 0 N--CA 1.45 -0.4 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.15 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.5 t -128.6 132.2 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.781 0.324 . . . . 0.0 111.106 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -84.36 110.64 18.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 109.954 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.683 HD22 ' CD1' ' A' ' 250' ' ' LEU . 50.8 mt -67.65 143.71 55.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.557 -179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -68.82 -24.07 64.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.254 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.423 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.3 OUTLIER -137.87 168.44 16.25 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.789 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.466 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 36.7 Cg_endo -65.68 70.9 0.34 Allowed 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.489 2.126 . . . . 0.0 112.119 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.683 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.65 24.02 6.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.173 -179.906 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.784 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -106.45 -167.8 22.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.442 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -118.86 -35.24 3.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.665 0.269 . . . . 0.0 111.188 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -121.31 167.05 13.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.163 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -97.17 25.85 5.19 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.019 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.32 17.22 12.85 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.868 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.13 156.37 47.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.795 0.331 . . . . 0.0 111.071 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.5 t -143.82 122.33 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.116 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.86 29.77 16.71 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.223 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 87.83 11.86 67.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.752 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 45.7 m -117.13 114.24 23.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.851 0.358 . . . . 0.0 110.818 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 45.6 ttp180 -88.15 112.45 22.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.836 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -87.32 -34.73 18.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 10.6 p90 -154.66 170.21 22.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.79 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 33.3 tp60 -105.0 129.26 53.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.83 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 8.3 p -154.2 164.68 38.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.125 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -60.79 165.23 6.12 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.915 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.1 132.11 33.06 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.36 2.04 . . . . 0.0 112.099 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 39.6 mmtm 64.11 17.19 10.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.227 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.466 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.2 m-85 -108.19 2.26 22.71 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.218 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -99.7 117.0 5.74 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.608 -0.806 . . . . 0.0 112.762 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.889 HD23 ' HB ' ' A' ' 220' ' ' VAL . 9.9 tp -124.79 131.35 53.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.779 0.323 . . . . 0.0 110.558 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.4 m-85 -111.03 112.82 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.458 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.899 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.65 148.87 51.7 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.866 0.365 . . . . 0.0 111.102 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.737 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.5 Cg_exo -48.21 162.54 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.003 2.468 . . . . 0.0 112.758 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.84 -36.86 66.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.852 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.541 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -73.08 -26.16 61.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.81 179.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.4 OUTLIER -77.88 -20.06 53.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.72 179.377 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.9 t -97.02 141.12 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.323 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 145.31 44.73 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.735 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.38 133.44 48.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.794 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.608 HD12 HD21 ' A' ' 219' ' ' LEU . 13.6 tt -88.28 -29.74 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.166 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.28 -136.2 12.56 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.528 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.608 0.242 . . . . 0.0 110.943 179.866 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -122.32 -78.66 0.6 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.722 0.296 . . . . 0.0 110.802 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.34 -9.0 10.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.441 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -140.9 162.39 35.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.818 0.342 . . . . 0.0 110.947 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 95.25 -9.59 69.71 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.835 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.482 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 4.2 mm-40 -96.1 29.21 2.86 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 122.878 -0.19 . . . . 0.0 111.027 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 2.3 pt-20 -141.81 153.17 44.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.954 0.407 . . . . 0.0 111.509 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.566 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.7 m-85 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.295 -0.86 . . . . 0.0 110.889 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.805 0.336 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.7 tt0 -72.91 147.39 45.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.525 HD22 HG11 ' A' ' 218' ' ' VAL . 90.9 mt -116.45 144.59 44.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.977 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.17 144.08 44.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.816 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.9 mt -60.85 136.32 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.093 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.63 -1.75 76.02 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.663 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -94.18 146.95 23.63 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.838 0.351 . . . . 0.0 111.116 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.696 ' HD3' HG22 ' A' ' 227' ' ' VAL . 2.6 tpp180 -76.91 133.93 39.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.514 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.654 HG21 HG11 ' A' ' 278' ' ' VAL . 8.3 m -153.39 -175.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.487 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.616 HD21 HD12 ' A' ' 281' ' ' ILE . 36.0 mt -123.91 121.38 35.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.183 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 111.39 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.953 0.406 . . . . 0.0 110.113 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.86 -6.53 82.82 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.535 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.72 -25.81 12.5 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.786 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 25.0 p -100.45 -27.53 13.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.894 0.378 . . . . 0.0 110.966 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.578 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.0 OUTLIER -99.75 146.91 26.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.517 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.53 141.01 50.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.035 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -171.64 -166.51 30.48 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.852 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.696 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.3 t -120.38 133.29 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 110.994 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.0 t -60.87 133.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.579 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -121.14 -45.04 2.37 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.488 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -147.14 137.63 23.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.852 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.4 mp -121.65 125.57 46.98 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 111.018 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 169.19 -174.09 43.63 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -79.77 161.34 25.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.917 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.652 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 33.3 p -107.59 161.91 14.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 -86.26 -4.1 59.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.335 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.672 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.31 -16.83 7.28 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.578 0.228 . . . . 0.0 111.465 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.652 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.3 142.14 49.37 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.813 0.339 . . . . 0.0 111.269 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.04 138.22 31.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.29 -162.71 12.68 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.537 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -98.54 135.02 40.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.83 0.348 . . . . 0.0 110.83 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 51.5 m95 -132.52 168.87 17.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.972 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . . . . . . . . . 42.4 t -139.14 156.03 47.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.036 0.446 . . . . 0.0 111.045 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.461 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.7 126.22 7.15 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.18 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.488 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.3 t -129.29 131.62 67.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.8 0.333 . . . . 0.0 111.079 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -84.3 110.67 18.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.963 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.476 HD11 HD22 ' A' ' 271' ' ' LEU . 83.8 mt -67.45 142.42 56.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.448 -178.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -68.81 -25.64 64.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.312 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.463 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.7 OUTLIER -135.33 169.4 13.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.909 -179.958 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.4 Cg_endo -66.65 67.86 0.51 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.473 2.115 . . . . 0.0 112.254 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.578 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.2 26.42 6.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.963 179.898 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.776 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.95 -158.74 22.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.562 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -126.07 -40.98 1.97 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.723 0.297 . . . . 0.0 111.231 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.91 174.09 6.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 111.133 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -100.72 25.71 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.14 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.44 17.62 14.95 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.816 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.06 157.9 45.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.911 0.386 . . . . 0.0 111.163 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.672 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -142.81 119.41 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.106 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.25 13.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.257 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.03 11.47 58.72 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.758 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 66.5 m -117.33 114.44 23.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.836 0.35 . . . . 0.0 110.779 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 65.7 ttp85 -88.65 110.74 21.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.814 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -84.38 -32.91 23.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.816 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.6 p90 -154.76 172.71 17.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.721 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 41.3 tp60 -104.69 128.08 52.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.848 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 18.0 p -154.26 161.62 41.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.436 ' HB2' ' CD2' ' A' ' 269' ' ' TYR . 12.6 mt-30 -60.83 165.79 5.44 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -64.04 133.46 38.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.418 2.079 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 2.8 mmtp 61.92 19.6 10.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.316 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.436 ' CD2' ' HB2' ' A' ' 266' ' ' GLN . 3.5 m-30 -106.78 -19.21 13.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.707 0.289 . . . . 0.0 111.003 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.96 130.51 10.24 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.89 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.1 tp -137.39 127.46 25.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.765 0.317 . . . . 0.0 110.512 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.1 m-85 -107.53 112.52 25.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.333 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.845 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.64 150.49 60.5 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 120.943 0.401 . . . . 0.0 111.106 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.722 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.0 Cg_exo -51.51 162.76 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.867 2.378 . . . . 0.0 112.564 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.53 -26.96 24.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.067 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.549 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -79.53 -26.57 41.45 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.005 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.0 mmtp -80.41 -19.65 45.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.872 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.9 t -94.61 144.25 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.009 0.433 . . . . 0.0 111.369 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.01 144.21 32.2 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.765 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.35 134.93 53.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.908 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.616 HD12 HD21 ' A' ' 219' ' ' LEU . 18.8 tt -89.99 -30.18 5.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.055 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 76.1 -138.82 23.3 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.471 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.331 -0.236 0 CA-C-O 120.621 0.248 . . . . 0.0 110.797 -179.981 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.414 0 CA-C-O 120.421 -0.099 . . . . 0.0 112.962 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 58.55 -167.01 0.15 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.835 0.35 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -115.82 169.96 8.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -129.23 163.08 26.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.776 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 83.06 26.0 46.48 Favored Glycine 0 C--N 1.33 0.237 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.414 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.516 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -88.32 19.29 3.86 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.526 0.195 . . . . 0.0 111.526 -179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.2 pm0 -132.59 151.43 51.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.965 0.412 . . . . 0.0 111.399 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.643 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.305 -0.855 . . . . 0.0 110.953 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.639 0.257 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -116.69 -60.13 1.89 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.02 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.543 HD22 HG11 ' A' ' 218' ' ' VAL . 70.0 mt -121.21 158.09 28.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.172 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.3 150.92 49.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.774 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 32.0 mt -65.99 143.65 15.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.118 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.91 -4.22 86.47 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.744 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -94.29 144.2 25.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.939 0.4 . . . . 0.0 111.255 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.525 ' HD3' HG22 ' A' ' 227' ' ' VAL . 11.2 tpp180 -76.73 135.54 39.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.456 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.698 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.81 -175.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.005 0.431 . . . . 0.0 111.617 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.706 HD21 HD12 ' A' ' 281' ' ' ILE . 38.5 mt -123.99 121.41 35.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.299 178.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.874 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.32 111.63 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.905 0.383 . . . . 0.0 110.069 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.98 -6.55 83.05 Favored Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.516 -179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.43 -25.51 12.72 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.761 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 23.4 p -100.83 -27.56 13.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.81 0.338 . . . . 0.0 110.922 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.58 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.77 147.7 25.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.596 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.445 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.4 146.8 45.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.823 0.344 . . . . 0.0 111.078 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.4 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -177.59 -167.3 35.59 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.677 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 217' ' ' ARG . 66.6 t -119.93 134.4 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.725 0.297 . . . . 0.0 111.024 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -62.48 126.61 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.527 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -113.88 -45.05 3.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.496 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -147.71 133.87 19.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.494 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -117.93 127.42 53.82 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.946 0.403 . . . . 0.0 111.003 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 168.33 -174.09 43.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.385 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.75 161.83 25.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.776 0.322 . . . . 0.0 110.815 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.625 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.8 p -108.77 163.49 13.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -87.05 -4.8 59.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.337 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.69 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -121.23 -17.04 7.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.603 0.24 . . . . 0.0 111.456 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.625 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.46 139.29 53.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.813 0.339 . . . . 0.0 111.186 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -88.92 133.33 34.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.949 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.34 -165.93 12.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.552 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -95.31 130.93 41.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 110.955 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.471 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 56.4 m95 -129.21 169.11 15.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.494 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.8 t -136.89 155.77 49.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.03 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.46 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.15 125.88 6.82 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.159 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.0 t -128.5 132.57 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.834 0.349 . . . . 0.0 111.014 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.4 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 35.6 tt0 -84.25 111.78 19.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.822 179.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.411 ' CD1' ' CA ' ' A' ' 251' ' ' GLY . 64.3 mt -67.51 142.45 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.557 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -68.77 -26.65 65.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.017 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.438 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.0 OUTLIER -135.15 168.85 15.67 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.669 179.937 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.422 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 38.2 Cg_endo -66.57 69.0 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.4 2.067 . . . . 0.0 112.172 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.58 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.25 28.23 6.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.097 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.685 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.36 -167.07 18.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.468 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.5 mmtt -118.69 -34.15 4.06 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.716 0.293 . . . . 0.0 111.202 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.95 171.33 8.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.941 0.4 . . . . 0.0 111.151 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -103.46 25.79 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.3 13.41 21.11 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.958 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 158.51 44.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.81 0.338 . . . . 0.0 111.234 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.69 HG11 ' CD1' ' A' ' 236' ' ' PHE . 45.3 t -139.04 119.4 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.152 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.9 26.59 13.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.268 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 96.29 -7.5 66.56 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.749 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 30.8 m -100.84 115.51 30.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.859 0.361 . . . . 0.0 110.807 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 8.4 ttm105 -86.79 127.88 35.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -101.9 -32.0 10.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.873 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 8.2 p90 -155.59 171.88 19.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.773 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 47.1 tp60 -104.78 128.7 53.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.963 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.0 p -154.39 160.56 41.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.764 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -60.77 165.15 6.2 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.756 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.89 129.74 31.83 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.451 2.101 . . . . 0.0 112.115 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.2 mmtt 61.71 20.39 11.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.381 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.3 m-85 -111.66 21.27 16.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -123.01 126.33 6.28 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.631 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -131.82 130.76 42.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.84 0.353 . . . . 0.0 110.669 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.7 m-85 -105.29 112.65 25.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.117 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.874 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.18 148.72 52.62 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-O 120.858 0.361 . . . . 0.0 111.153 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.694 ' O ' HG23 ' A' ' 278' ' ' VAL . 72.0 Cg_exo -47.81 162.57 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.98 2.453 . . . . 0.0 112.683 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.54 -34.29 56.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.895 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.564 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -75.65 -26.17 57.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.458 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.9 OUTLIER -77.97 -20.06 53.38 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.837 179.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.698 HG11 HG21 ' A' ' 218' ' ' VAL . 21.9 t -95.57 140.88 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.157 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.18 147.65 49.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.852 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.92 133.2 46.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.797 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.706 HD12 HD21 ' A' ' 219' ' ' LEU . 16.4 tt -94.83 -25.21 4.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.184 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -88.27 -178.04 47.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.363 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.724 0.297 . . . . 0.0 110.746 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.92 117.21 10.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.93 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.32 -42.05 94.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -90.66 162.58 14.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 105.22 -2.52 40.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.642 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.48 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.2 mt-10 -96.18 25.75 4.69 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.661 0.231 . . . . 0.0 111.056 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.448 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -140.2 153.85 46.73 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.969 0.414 . . . . 0.0 111.379 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 40.6 m-85 . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.961 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . 0.483 ' CG ' HG22 ' A' ' 275' ' ' VAL . 1.5 tpm_? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.804 0.335 . . . . 0.0 110.986 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -177.59 96.07 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.821 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 77.8 mt -112.47 146.52 38.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.966 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.7 145.16 47.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.704 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 27.3 mt -61.03 140.04 19.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.064 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 88.12 -1.6 84.82 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.679 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -94.12 145.92 24.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.868 0.366 . . . . 0.0 110.933 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 13.8 tpp85 -76.63 135.51 39.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.54 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.671 HG21 HG11 ' A' ' 278' ' ' VAL . 10.5 m -153.74 -175.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.439 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.492 HD21 HD12 ' A' ' 281' ' ' ILE . 26.3 mt -122.79 121.53 36.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.278 178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.918 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.53 111.62 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.917 0.389 . . . . 0.0 109.998 179.517 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.96 -6.62 83.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.528 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.55 -25.33 13.44 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.81 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 13.0 p -103.38 -25.39 13.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.811 0.339 . . . . 0.0 110.879 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.458 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.83 147.5 25.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.389 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -120.16 143.98 47.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.349 . . . . 0.0 111.042 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.02 -165.91 30.69 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.806 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 53.1 t -122.54 131.91 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.801 0.334 . . . . 0.0 110.944 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 22.4 t -59.83 132.46 25.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.482 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 4.8 mmt180 -120.94 -40.2 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.559 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -152.52 137.7 17.4 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.811 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.446 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.2 mp -121.48 122.22 39.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.371 . . . . 0.0 111.022 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.15 -176.88 46.55 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.419 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -79.78 163.32 24.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.847 0.356 . . . . 0.0 110.977 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.535 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.2 p -110.67 167.35 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -92.11 -4.16 54.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.445 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.607 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -120.91 -16.93 8.01 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 116.681 -0.236 . . . . 0.0 111.441 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.535 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.61 141.83 49.97 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.815 0.34 . . . . 0.0 111.279 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.1 mtpm? -89.13 135.52 33.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.883 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 109.63 -168.7 13.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.648 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -93.41 133.85 36.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.493 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 62.6 m95 -129.58 168.21 16.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.446 ' SG ' HD23 ' A' ' 231' ' ' LEU . 41.4 t -136.82 156.15 48.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 110.998 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.86 125.74 6.91 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.267 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.427 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.05 132.21 67.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.81 0.338 . . . . 0.0 110.967 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 44.3 tt0 -84.39 110.65 18.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.945 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.637 HD22 ' CD1' ' A' ' 250' ' ' LEU . 61.0 mt -67.49 145.47 54.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.064 0.459 . . . . 0.0 111.458 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -69.68 -26.98 64.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.431 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 0.6 OUTLIER -134.4 169.02 14.96 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.839 -179.907 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.44 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 39.5 Cg_endo -66.57 70.01 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.462 2.108 . . . . 0.0 112.172 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.637 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 25.81 6.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.099 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.84 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.81 -159.1 22.61 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.525 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.9 mmtt -124.97 -40.7 2.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 111.178 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.93 171.26 8.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.899 0.38 . . . . 0.0 111.068 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -97.46 25.6 5.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.053 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.49 19.71 10.24 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.786 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.21 159.04 43.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.855 0.36 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.607 HG11 ' CD1' ' A' ' 236' ' ' PHE . 58.2 t -143.24 120.38 5.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.015 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.71 26.96 13.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.303 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 92.03 10.85 60.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.812 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 9.3 m -117.34 115.45 25.26 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.813 0.34 . . . . 0.0 110.975 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -87.86 115.37 25.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -88.55 -40.37 13.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.853 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 7.7 p90 -147.34 170.9 16.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.718 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.72 129.5 52.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.846 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 26.7 p -154.39 164.17 39.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.015 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -60.69 165.14 6.1 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -61.64 128.8 25.67 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt 64.81 16.43 10.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.238 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.44 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 3.3 m-85 -107.31 13.79 26.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.683 0.277 . . . . 0.0 111.211 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -111.72 112.57 3.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.683 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.7 tp -119.81 128.8 54.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.826 0.346 . . . . 0.0 110.726 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.2 m-85 -106.37 112.69 25.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.101 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.866 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.8 148.67 56.39 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.844 0.354 . . . . 0.0 111.098 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.745 ' O ' HG23 ' A' ' 278' ' ' VAL . 50.7 Cg_exo -50.87 162.73 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.882 2.388 . . . . 0.0 112.681 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . 0.483 HG22 ' CG ' ' A' ' 210' ' ' ARG . 10.1 p -71.1 -28.96 34.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.939 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.577 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.77 -24.97 52.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.072 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.439 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -84.22 -20.02 33.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.954 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.5 t -91.94 142.23 13.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.98 0.419 . . . . 0.0 111.253 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.07 149.26 37.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.938 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -74.09 134.37 42.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.712 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.492 HD12 HD21 ' A' ' 219' ' ' LEU . 5.1 tt -88.22 -35.25 7.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 61.68 -89.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.821 -0.705 . . . . 0.0 112.456 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.624 0.25 . . . . 0.0 110.889 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.42 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -116.51 164.16 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.782 0.325 . . . . 0.0 111.001 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.44 32.85 5.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -139.18 162.79 34.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 90.08 18.05 51.52 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.72 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.474 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 5.7 mm-40 -106.13 26.76 9.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.574 0.226 . . . . 0.0 110.971 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.1 OUTLIER -142.29 156.92 45.3 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.991 0.424 . . . . 0.0 111.311 -179.755 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.611 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.7 m-85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.198 -0.906 . . . . 0.0 110.938 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.743 0.306 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.7 179.98 8.14 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.827 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 79.8 mt -121.76 144.58 48.72 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.894 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.46 145.81 31.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 30.2 mt -65.96 132.19 31.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.041 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 96.05 0.28 61.91 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.704 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.18 147.73 22.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.892 0.377 . . . . 0.0 111.093 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.6 ' HD3' HG22 ' A' ' 227' ' ' VAL . 8.3 tpp85 -76.53 130.29 37.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.426 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -150.74 -175.86 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.619 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.2 mt -124.51 121.24 34.28 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.227 178.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -87.87 112.0 22.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.939 0.399 . . . . 0.0 110.05 179.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.82 -6.7 82.39 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.528 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.27 -24.63 15.47 Favored Glycine 0 C--N 1.333 0.406 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.741 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.3 p -101.23 -28.12 12.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.864 0.364 . . . . 0.0 111.044 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.44 ' HD3' HD12 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.86 147.56 25.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.453 ' HA ' HD23 ' A' ' 219' ' ' LEU . . . -118.9 143.91 46.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.024 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.24 -168.27 34.87 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.4 -0.905 . . . . 0.0 112.95 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.6 HG22 ' HD3' ' A' ' 217' ' ' ARG . 71.0 t -119.47 133.61 65.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.808 0.337 . . . . 0.0 110.959 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.457 HG13 ' SG ' ' A' ' 242' ' ' CYS . 24.0 t -61.28 133.24 27.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -121.13 -45.09 2.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.625 -179.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -146.78 132.95 19.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.863 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.7 mp -117.5 127.61 54.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.888 0.375 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 167.41 -174.24 42.55 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -79.78 159.41 26.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.773 0.32 . . . . 0.0 110.877 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.611 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.1 p -106.62 161.2 14.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.93 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.68 -2.62 58.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.363 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.53 -17.4 6.99 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.587 0.232 . . . . 0.0 111.389 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.611 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.66 145.32 47.55 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.784 0.326 . . . . 0.0 111.244 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.83 140.98 29.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.852 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 105.81 -161.57 14.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.592 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.17 135.33 39.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.917 0.389 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.487 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 54.6 m95 -132.26 168.67 17.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.457 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.2 t -139.48 155.95 47.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.45 . . . . 0.0 111.039 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.462 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.73 126.7 7.36 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.104 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.507 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.3 132.07 67.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.064 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -84.46 111.87 19.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.831 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.436 HD21 HD22 ' A' ' 271' ' ' LEU . 52.5 mt -67.55 155.49 38.98 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.49 -178.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -77.97 -29.92 50.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.12 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.4 ' O ' ' N ' ' A' ' 250' ' ' LEU . 0.4 OUTLIER -133.6 170.56 11.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 179.962 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.4 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 18.9 Cg_exo -64.89 69.43 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.672 2.248 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.44 HD12 ' HD3' ' A' ' 224' ' ' LYS . 0.3 OUTLIER -126.46 23.62 6.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.227 -179.804 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.788 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.65 -167.55 23.53 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.37 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 17.0 mmtt -118.33 -34.42 4.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.733 0.301 . . . . 0.0 111.306 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.18 169.0 12.16 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.898 0.38 . . . . 0.0 111.168 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -97.32 25.68 5.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.113 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.34 17.59 12.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.862 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.04 43.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.859 0.361 . . . . 0.0 111.054 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.1 t -145.37 121.27 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.122 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.66 26.14 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.315 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 95.56 -10.01 68.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.814 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 11.6 m -98.47 118.44 35.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.774 0.321 . . . . 0.0 110.872 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.7 ttp-105 -90.0 121.24 31.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.793 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -95.26 -32.21 13.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.952 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 7.8 p90 -156.94 169.05 25.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 53.7 tp60 -104.87 127.75 52.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.902 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.0 p -154.37 162.73 41.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.433 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.5 mm-40 -60.88 165.57 5.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.82 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -64.99 137.23 51.88 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.356 2.037 . . . . 0.0 112.178 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 11.6 mmmt 62.02 21.46 12.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.313 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.2 m-85 -111.47 -19.23 12.64 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.092 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.49 117.72 4.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.693 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -126.63 125.8 42.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.51 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 6.7 m-85 -104.76 112.62 25.79 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.355 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.86 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.98 147.14 46.67 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.749 0.309 . . . . 0.0 111.08 179.184 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 63.4 Cg_exo -49.08 162.77 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 123.021 2.481 . . . . 0.0 112.638 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.3 p -71.39 -30.72 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.957 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.555 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -76.16 -27.52 57.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.867 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.449 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.5 mmpp? -79.53 -19.9 48.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.903 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -94.02 141.29 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.337 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.95 144.75 43.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.788 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -68.92 135.14 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.779 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.419 HG21 ' CG ' ' A' ' 217' ' ' ARG . 16.3 tt -88.55 -3.46 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.528 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.86 74.93 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.473 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 2.5 p90 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.688 0.28 . . . . 0.0 110.795 -179.935 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.18 -53.57 1.83 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -109.09 -31.61 7.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -122.86 162.21 22.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 106.95 -22.17 30.33 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.653 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.518 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 6.2 mm-40 -95.16 23.41 5.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.493 0.187 . . . . 0.0 111.213 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.0 OUTLIER -132.73 154.97 49.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.975 0.416 . . . . 0.0 111.36 -179.787 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.618 ' O ' HD12 ' A' ' 271' ' ' LEU . 50.2 m-85 . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.927 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.844 0.354 . . . . 0.0 110.799 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -87.61 -53.1 4.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 81.5 mt -117.23 154.72 30.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.019 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.9 145.84 49.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.415 HG23 ' HA ' ' A' ' 229' ' ' ARG . 31.5 mt -63.94 138.83 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.163 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 89.7 -1.71 81.58 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.84 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -94.08 146.37 24.01 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.878 0.37 . . . . 0.0 111.153 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.613 ' HD3' HG22 ' A' ' 227' ' ' VAL . 14.5 tpp180 -76.67 130.49 37.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.584 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.658 HG21 HG11 ' A' ' 278' ' ' VAL . 8.9 m -148.66 -176.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.461 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.518 HD21 HD12 ' A' ' 281' ' ' ILE . 32.7 mt -124.27 121.14 34.21 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.11 178.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.909 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -89.04 111.06 22.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.97 0.414 . . . . 0.0 110.237 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.49 -6.46 83.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.562 -179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.35 -25.24 13.2 Favored Glycine 0 C--N 1.334 0.457 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.767 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 20.3 p -101.61 -26.48 13.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.531 ' HE2' HD13 ' A' ' 250' ' ' LEU . 1.1 mmpt? -99.75 147.23 25.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.523 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.45 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.65 142.32 50.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.159 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.408 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.17 -165.45 30.11 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.911 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.613 HG22 ' HD3' ' A' ' 217' ' ' ARG . 77.0 t -120.55 133.21 67.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.785 0.326 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 25.7 t -60.77 132.4 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.495 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.415 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.6 mmt180 -121.13 -45.32 2.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.523 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -147.64 132.3 17.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.931 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.504 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.3 mp -116.56 122.18 43.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 0.0 110.984 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.97 -175.21 46.51 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.495 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -79.74 160.63 26.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.371 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 30.2 p -106.66 165.2 11.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -90.47 -0.63 57.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.414 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.471 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.13 -17.17 6.28 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 120.545 0.212 . . . . 0.0 111.526 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.543 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 142.17 49.57 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.863 0.364 . . . . 0.0 111.24 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt -87.9 135.82 33.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.809 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.14 -162.01 12.76 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.435 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -99.89 142.07 31.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.767 0.318 . . . . 0.0 110.92 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.404 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 52.5 m95 -138.72 169.01 18.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.924 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.504 ' SG ' HD23 ' A' ' 231' ' ' LEU . 40.4 t -135.82 156.1 49.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.039 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.62 126.38 7.11 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.23 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.4 t -129.1 132.65 66.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.745 0.307 . . . . 0.0 111.102 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.408 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 20.0 tt0 -84.32 110.85 18.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.966 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.468 HD12 ' CA ' ' A' ' 251' ' ' GLY . 96.3 mt -67.31 143.8 56.22 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.123 0.487 . . . . 0.0 111.499 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -71.81 -25.81 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.288 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.468 ' HB3' HD23 ' A' ' 250' ' ' LEU . 0.6 OUTLIER -136.46 170.01 11.98 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.902 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.465 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.9 Cg_endo -66.4 67.3 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.517 2.145 . . . . 0.0 112.429 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.531 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.45 6.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.943 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.697 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -109.76 -159.96 18.28 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.587 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt -126.05 -40.85 1.98 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.777 0.322 . . . . 0.0 111.304 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -116.69 172.53 7.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.94 0.4 . . . . 0.0 111.16 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -102.13 25.7 8.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.53 15.72 20.08 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.73 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -136.8 158.95 43.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.797 0.332 . . . . 0.0 111.209 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.471 HG11 ' CD1' ' A' ' 236' ' ' PHE . 65.8 t -145.07 118.67 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.039 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.34 28.46 16.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.26 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 90.46 11.94 61.83 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.69 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 17.6 m -117.37 113.85 22.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.758 0.313 . . . . 0.0 110.815 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 18.3 ttm105 -89.81 110.64 21.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.801 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 58.3 m-85 -84.74 -33.63 23.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.957 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.453 ' CE1' ' HA3' ' A' ' 243' ' ' GLY . 6.8 p90 -153.21 172.8 16.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.1 tp60 -104.81 127.33 52.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.929 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 22.2 p -154.27 161.81 41.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.965 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 267' ' ' PRO . 10.0 mm-40 -60.86 165.29 6.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.815 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 266' ' ' GLN . 36.4 Cg_endo -65.42 134.25 37.96 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.339 2.026 . . . . 0.0 112.126 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 6.6 mmtm 61.34 22.67 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.465 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.57 -19.36 12.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.118 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -79.83 132.27 11.24 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.857 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.909 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -137.11 129.4 29.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.836 0.351 . . . . 0.0 110.677 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 450' ' ' GLU . 6.3 m-85 -106.26 112.59 25.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.171 -179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.853 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.04 149.79 56.93 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.88 0.372 . . . . 0.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.725 ' O ' HG23 ' A' ' 278' ' ' VAL . 44.5 Cg_exo -53.47 163.23 2.72 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.864 2.376 . . . . 0.0 112.605 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.23 -41.03 83.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.584 179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.555 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -65.85 -26.02 67.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.231 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.467 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mtpm? -82.87 -19.91 36.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.813 0.339 . . . . 0.0 110.76 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.2 t -97.98 140.6 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.986 0.422 . . . . 0.0 111.441 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.55 146.83 40.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.85 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.96 130.18 42.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.846 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.518 HD12 HD21 ' A' ' 219' ' ' LEU . 6.5 tt -79.71 -17.48 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.209 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 110.14 -164.2 12.33 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.441 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 9.5 p90 . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.636 0.255 . . . . 0.0 110.841 -179.953 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -62.5 179.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -108.49 78.87 1.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -132.96 162.52 31.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 113.17 -21.85 16.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.665 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 3.1 mt-10 -96.49 28.91 3.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.517 0.199 . . . . 0.0 111.091 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -141.21 152.37 44.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.029 0.442 . . . . 0.0 111.33 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.676 ' O ' HD12 ' A' ' 271' ' ' LEU . 41.7 m-85 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.303 -0.856 . . . . 0.0 110.904 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.901 0.382 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -63.69 169.02 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.847 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.487 HD22 HG11 ' A' ' 218' ' ' VAL . 95.2 mt -118.5 150.69 39.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.28 146.68 51.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.782 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.703 HG23 ' HA ' ' A' ' 229' ' ' ARG . 62.1 mt -57.0 132.51 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 97.59 -2.14 60.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.574 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -94.08 143.51 26.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.798 0.332 . . . . 0.0 111.008 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.469 ' HD3' HG22 ' A' ' 227' ' ' VAL . 12.3 tpp180 -76.6 132.9 39.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.506 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.618 HG21 HG11 ' A' ' 278' ' ' VAL . 11.8 m -153.93 -175.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.079 0.466 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.638 HD21 HD12 ' A' ' 281' ' ' ILE . 41.5 mt -124.21 121.32 34.76 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.346 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.89 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -86.73 111.63 21.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.867 0.365 . . . . 0.0 110.123 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.75 -6.43 82.78 Favored Glycine 0 CA--C 1.519 0.327 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.479 -179.232 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.88 -27.19 9.24 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.875 -0.678 . . . . 0.0 112.758 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 34.0 p -99.32 -27.99 13.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.73 0.3 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.422 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.3 mmpt? -99.86 148.91 23.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.687 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.33 144.58 46.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -174.92 -169.35 36.72 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.645 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.469 HG22 ' HD3' ' A' ' 217' ' ' ARG . 63.0 t -119.88 134.22 64.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.935 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.448 HG13 ' SG ' ' A' ' 242' ' ' CYS . 23.7 t -61.24 131.41 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.719 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -119.58 -35.44 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.39 -179.286 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -151.77 148.02 27.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.482 -0.327 . . . . 0.0 110.813 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.95 124.57 26.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.921 0.391 . . . . 0.0 110.991 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 166.65 -176.15 41.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.449 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.73 153.74 29.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.81 0.338 . . . . 0.0 110.817 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.473 HG23 ' CG ' ' A' ' 241' ' ' TRP . 25.6 p -100.99 170.42 8.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.58 2.02 55.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.441 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.628 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.25 -17.27 6.19 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.736 -0.211 . . . . 0.0 111.417 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.44 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -120.95 145.9 47.23 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.855 0.36 . . . . 0.0 111.168 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 17.3 mtmt -93.88 120.93 34.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.21 -165.69 18.26 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.578 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -91.08 135.56 33.68 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.829 0.347 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.473 ' CG ' HG23 ' A' ' 234' ' ' THR . 69.5 m95 -133.55 163.83 28.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.92 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.448 ' SG ' HG13 ' A' ' 228' ' ' VAL . 30.9 t -137.92 154.95 49.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.087 0.47 . . . . 0.0 110.93 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.456 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -113.85 127.52 7.85 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.709 -0.678 . . . . 0.0 112.103 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.11 131.16 68.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.787 0.327 . . . . 0.0 111.064 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -84.27 111.45 19.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.941 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.547 HD13 HD12 ' A' ' 250' ' ' LEU . 93.1 mt -68.04 143.35 55.56 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.004 0.431 . . . . 0.0 111.445 -179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -68.88 -25.96 64.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.155 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.424 ' CB ' HD23 ' A' ' 250' ' ' LEU . 4.5 mt-10 -134.54 168.16 19.19 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.917 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 40.3 Cg_endo -67.03 69.26 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.579 2.186 . . . . 0.0 112.044 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.547 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.62 28.65 5.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.11 -179.843 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.758 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -107.82 -158.75 20.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.585 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.0 mmtt -126.08 -42.32 1.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 111.106 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -114.76 172.98 6.71 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.132 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 17.9 p-10 -100.76 25.53 7.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.264 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.47 18.95 10.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.952 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.12 159.08 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.913 0.387 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.628 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.8 t -141.74 121.5 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.21 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.95 26.72 13.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.283 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.57 7.14 65.26 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.802 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 75.1 m -115.96 116.34 27.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.752 0.311 . . . . 0.0 110.759 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 15.8 ttp180 -85.49 127.98 34.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -101.5 -35.28 9.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.505 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.1 p90 -152.56 169.23 23.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.747 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -105.2 130.58 53.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.005 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 5.1 p -154.39 166.14 34.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -60.81 165.06 6.38 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.726 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.95 129.05 26.03 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.415 2.077 . . . . 0.0 111.755 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.1 mmtp 63.65 18.47 11.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.218 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.2 m-85 -109.25 16.94 22.06 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.002 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -117.83 116.15 3.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.701 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.89 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.2 tp -123.08 125.77 45.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.505 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 6.2 m-85 -100.23 112.72 25.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.346 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.792 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -138.93 150.6 65.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.89 0.376 . . . . 0.0 111.073 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.47 ' HG2' ' CD2' ' A' ' 276' ' ' HIS . 35.5 Cg_endo -66.57 162.16 38.14 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.756 2.304 . . . . 0.0 112.569 -179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 9.4 p -62.66 -31.78 53.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.806 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.47 ' CD2' ' HG2' ' A' ' 274' ' ' PRO . 1.3 p-80 -73.99 -7.24 51.68 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.599 0.237 . . . . 0.0 111.576 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 274' ' ' PRO . 0.0 OUTLIER -108.16 -19.29 13.54 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.638 0.256 . . . . 0.0 111.157 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.618 HG11 HG21 ' A' ' 218' ' ' VAL . 40.5 t -96.11 140.12 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.129 0.49 . . . . 0.0 111.267 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.33 150.43 39.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.792 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -71.42 128.48 36.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.638 HD12 HD21 ' A' ' 219' ' ' LEU . 2.1 tt -73.89 -30.15 27.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.193 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 159.06 105.85 0.22 Allowed Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.556 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 1.2 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.626 0.25 . . . . 0.0 110.872 179.931 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -155.49 127.64 7.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -112.39 -41.67 3.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.757 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -90.99 162.66 14.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.791 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 103.34 17.09 18.76 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.766 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.457 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.2 mt-10 -105.37 18.65 21.91 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 122.923 -0.163 . . . . 0.0 110.994 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.56 158.21 44.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.865 0.364 . . . . 0.0 111.354 -179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.582 ' O ' HD12 ' A' ' 271' ' ' LEU . 35.9 m-85 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.93 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.76 -27.0 9.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 82.9 mt -107.82 149.39 28.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.838 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 147.69 44.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.718 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.476 HG23 ' HA ' ' A' ' 229' ' ' ARG . 48.6 mt -61.8 144.68 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 84.45 0.62 89.39 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.73 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -94.12 144.2 25.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.887 0.375 . . . . 0.0 111.072 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.567 ' HD3' HG22 ' A' ' 227' ' ' VAL . 7.1 tpp85 -76.75 132.51 39.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.48 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.663 HG21 HG11 ' A' ' 278' ' ' VAL . 10.2 m -152.47 -175.68 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.468 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 281' ' ' ILE . 41.3 mt -124.21 121.47 35.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.344 178.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.848 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.14 111.6 22.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.959 0.409 . . . . 0.0 110.071 179.424 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.06 -6.55 83.1 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.554 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.83 -26.58 10.57 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.733 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 32.6 p -100.12 -27.51 13.5 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.79 0.328 . . . . 0.0 110.943 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.408 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.2 mmpt? -99.73 147.33 25.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.684 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.455 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.44 145.87 45.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.119 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -175.88 -167.12 34.35 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.702 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.567 HG22 ' HD3' ' A' ' 217' ' ' ARG . 68.9 t -121.61 132.77 69.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.858 0.361 . . . . 0.0 110.997 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 30.6 t -59.64 133.22 25.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.488 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.476 ' HA ' HG23 ' A' ' 214' ' ' ILE . 4.2 mmt180 -121.06 -42.07 2.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.47 -179.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -149.87 132.51 15.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.83 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.522 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -118.36 132.45 56.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.869 0.366 . . . . 0.0 111.099 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 159.5 -173.78 36.3 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -79.73 157.93 27.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.729 0.299 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 18.7 p -104.68 170.96 7.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -95.34 1.5 54.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.433 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.57 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.09 -17.47 6.2 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.729 -0.214 . . . . 0.0 111.564 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . . . . . . . . . . . -121.14 145.64 47.6 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.763 0.316 . . . . 0.0 111.169 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.47 121.03 33.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.862 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 125.83 -167.82 18.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.628 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -94.47 135.26 36.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 50.3 m95 -133.79 169.04 17.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.958 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.522 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.5 t -136.82 154.33 50.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.101 0.476 . . . . 0.0 111.038 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.446 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.38 127.21 7.64 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.137 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.7 t -129.23 132.57 66.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.829 0.347 . . . . 0.0 111.09 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -84.41 110.91 18.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.257 -0.428 . . . . 0.0 109.958 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.562 HD22 ' CD1' ' A' ' 250' ' ' LEU . 55.9 mt -67.85 145.04 55.01 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.123 0.487 . . . . 0.0 111.512 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -69.93 -28.54 65.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.202 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 269' ' ' TYR . 1.4 mt-10 -132.99 170.68 10.76 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.81 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -66.3 68.5 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.585 2.19 . . . . 0.0 111.853 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.562 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.58 28.86 5.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.227 -179.814 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.97 -164.25 17.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.547 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 26.3 mmtt -118.69 -38.16 3.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.765 0.316 . . . . 0.0 111.098 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -124.85 170.22 11.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.097 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 15.6 p-10 -97.33 25.87 5.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.139 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.18 20.61 8.58 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.899 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 156.54 47.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.884 0.373 . . . . 0.0 111.207 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.57 HG11 ' CD1' ' A' ' 236' ' ' PHE . 46.6 t -140.21 116.62 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.57 24.41 11.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.366 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 100.1 -5.79 57.9 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.849 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 4.5 m -101.32 115.18 29.92 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.737 0.303 . . . . 0.0 110.913 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -89.9 114.66 26.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.803 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -88.29 -40.46 13.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 6.7 p90 -145.07 168.57 20.0 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.703 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -104.74 128.27 52.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.3 p -154.15 162.37 41.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -60.82 165.15 6.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_exo -61.41 131.64 37.12 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.515 2.144 . . . . 0.0 112.043 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 24.3 mmtt 63.05 17.55 10.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.261 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 248' ' ' GLU . 3.2 m-85 -110.15 19.84 18.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.883 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -121.5 123.84 5.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.537 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.847 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.0 tp -130.88 125.86 34.67 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.65 112.49 25.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.998 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.848 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -139.96 150.08 61.05 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.845 0.355 . . . . 0.0 111.362 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.719 ' O ' HG23 ' A' ' 278' ' ' VAL . 51.3 Cg_exo -51.02 162.88 0.95 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.928 2.419 . . . . 0.0 112.587 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.2 p -71.85 -28.0 29.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.104 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.553 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.8 p-80 -78.45 -26.74 46.25 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.013 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 1.7 mmtp -80.91 -19.75 43.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.881 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.7 t -93.88 143.4 11.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.958 0.409 . . . . 0.0 111.162 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.74 146.44 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.906 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.73 131.63 44.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.681 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 219' ' ' LEU . 3.6 tt -81.56 -29.0 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.193 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 133.92 -123.8 3.41 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.487 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.698 0.285 . . . . 0.0 110.858 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 61.11 30.91 19.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.79 0.329 . . . . 0.0 110.964 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -150.74 30.4 0.66 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.753 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -97.03 163.07 13.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 97.8 24.82 11.34 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.459 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.504 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.1 mm-40 -101.59 21.84 13.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.46 0.171 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -138.74 152.85 48.32 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.046 0.451 . . . . 0.0 111.33 -179.734 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.572 ' O ' HD12 ' A' ' 271' ' ' LEU . 39.8 m-85 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.239 -0.886 . . . . 0.0 110.877 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.823 0.345 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -155.64 178.37 10.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.79 153.76 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 2.5 mtpt -118.27 146.34 44.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.592 HG23 ' HA ' ' A' ' 229' ' ' ARG . 61.2 mt -63.16 144.61 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.025 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.36 -1.91 87.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.763 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -94.13 143.23 26.56 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.827 0.346 . . . . 0.0 111.188 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.524 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.2 OUTLIER -76.65 132.58 39.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.437 179.655 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.662 HG21 HG11 ' A' ' 278' ' ' VAL . 10.1 m -151.04 -175.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.54 -179.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 36.8 mt -123.97 121.34 35.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.223 178.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.856 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -88.3 111.64 22.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.937 0.398 . . . . 0.0 110.126 179.609 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.96 -6.7 82.72 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.527 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.25 -25.26 12.95 Favored Glycine 0 C--N 1.335 0.478 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.765 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 30.6 p -101.06 -27.76 13.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.895 0.379 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.403 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.9 mmpt? -99.74 147.74 25.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.612 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -119.1 147.92 43.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.236 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -177.52 -164.05 30.4 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.568 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.524 HG22 ' HD3' ' A' ' 217' ' ' ARG . 70.6 t -125.29 134.18 67.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.959 0.409 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 23.1 t -60.85 132.43 26.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.549 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.592 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -121.2 -41.89 2.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.408 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -150.18 138.31 20.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.64 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.537 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.1 mp -122.66 125.99 46.72 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.889 0.376 . . . . 0.0 111.119 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 172.41 178.4 42.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -79.82 153.18 29.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.752 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 20.4 p -100.89 160.61 14.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.881 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -83.63 -31.49 26.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.029 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.522 ' CE1' HG11 ' A' ' 257' ' ' VAL . 0.1 OUTLIER -89.84 -17.55 27.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.533 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.752 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -121.46 148.17 44.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.817 0.341 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 5.8 pttp -96.21 139.37 32.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 106.31 -173.88 20.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.575 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -87.61 134.69 33.59 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.818 0.342 . . . . 0.0 110.919 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . . . . . . . . . 62.4 m95 -132.41 165.09 25.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.968 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.537 ' SG ' HD23 ' A' ' 231' ' ' LEU . 44.8 t -134.29 156.06 49.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.035 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.449 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.67 126.44 7.25 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.219 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.497 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.0 t -129.14 132.17 67.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -84.11 111.44 19.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.902 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.441 HD22 ' CD1' ' A' ' 250' ' ' LEU . 66.9 mt -67.72 142.59 56.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.536 -178.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -68.74 -25.05 64.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.219 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 6.7 mt-10 -135.78 170.41 11.11 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -67.43 69.71 0.68 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.598 2.199 . . . . 0.0 111.92 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.441 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.46 23.01 6.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.442 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.815 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.3 -174.6 24.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.421 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 4.8 mmtp -113.74 -28.74 7.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.775 0.322 . . . . 0.0 111.279 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -125.01 166.27 16.65 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.859 0.361 . . . . 0.0 111.175 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -99.73 25.83 6.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.959 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 107.19 15.75 15.2 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.828 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.17 158.39 44.41 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.773 0.321 . . . . 0.0 111.173 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.522 HG11 ' CE1' ' A' ' 236' ' ' PHE . 46.5 t -140.97 116.09 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 59.01 27.31 16.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.336 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.37 11.25 58.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.772 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 26.9 m -117.14 113.71 22.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.822 0.344 . . . . 0.0 110.826 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 33.2 ttm180 -88.12 114.03 24.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -88.28 -39.38 14.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.992 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.2 p90 -147.37 173.64 12.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.785 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 11.1 tp-100 -104.9 128.09 52.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.924 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 7.4 p -154.19 158.74 40.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.872 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -60.8 164.98 6.49 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.03 128.2 25.79 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.534 2.156 . . . . 0.0 112.22 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 1.3 mmpt? 65.6 14.31 9.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.464 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -105.79 17.28 23.96 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.634 0.254 . . . . 0.0 110.949 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -118.04 125.79 6.61 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.723 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.856 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -133.08 125.91 30.64 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.786 0.327 . . . . 0.0 110.586 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -101.83 112.53 25.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.267 -179.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.856 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.41 148.03 52.06 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.839 0.352 . . . . 0.0 110.938 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.759 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.9 Cg_exo -49.44 162.62 0.53 Allowed 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.98 2.453 . . . . 0.0 112.715 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -70.91 -33.05 50.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.873 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.559 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.7 p-80 -74.73 -27.08 60.21 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.909 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.485 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -78.92 -19.88 50.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.688 179.512 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 274' ' ' PRO . 20.0 t -95.9 143.73 11.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.322 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.98 139.43 30.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.792 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 2.3 mtpt -63.3 129.96 42.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.717 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 13.6 tt -77.32 -29.41 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.204 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -64.4 -114.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.671 -0.775 . . . . 0.0 112.591 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.675 0.274 . . . . 0.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.5 -172.08 0.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -178.16 -39.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -140.98 162.44 35.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 98.23 -9.18 63.05 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.91 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.485 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.4 mt-10 -95.83 28.71 2.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.702 0.251 . . . . 0.0 110.974 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.2 OUTLIER -140.83 152.41 45.12 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.943 0.401 . . . . 0.0 111.333 -179.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.587 ' O ' HD12 ' A' ' 271' ' ' LEU . 43.3 m-85 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.957 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 62.47 -174.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 31.4 mt -120.32 145.83 46.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.85 140.77 36.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.435 HG23 ' HA ' ' A' ' 229' ' ' ARG . 44.4 mt -61.94 148.98 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.004 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 79.73 1.79 87.39 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.704 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -94.03 144.57 25.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.877 0.37 . . . . 0.0 111.098 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -76.62 133.31 39.67 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.478 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.696 HG21 HG11 ' A' ' 278' ' ' VAL . 8.5 m -153.73 -176.95 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.5 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 278' ' ' VAL . 41.1 mt -124.16 121.5 35.3 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.191 178.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.887 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.25 111.76 22.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.98 0.419 . . . . 0.0 110.136 179.466 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.74 -6.55 82.53 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.502 -179.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.54 -26.63 10.1 Favored Glycine 0 C--N 1.333 0.399 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.792 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.6 p -99.51 -27.53 13.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.861 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.456 ' HB3' HD22 ' A' ' 246' ' ' LEU . 1.2 mmpt? -99.87 146.57 26.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.729 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.457 ' HB2' HD22 ' A' ' 219' ' ' LEU . . . -119.6 143.34 47.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.009 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -173.63 -166.65 32.21 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.773 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . . . . . . . . . 67.3 t -121.69 134.74 64.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.421 HG11 HD21 ' A' ' 231' ' ' LEU . 37.1 t -61.33 132.44 26.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.494 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.59 -45.09 2.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.329 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -147.33 135.71 21.69 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.708 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.595 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.0 OUTLIER -121.66 133.49 54.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.949 0.404 . . . . 0.0 111.059 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.61 -174.47 38.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.381 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -79.78 158.58 26.81 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.94 0.4 . . . . 0.0 110.731 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.567 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 34.2 p -105.99 165.58 11.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.009 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -90.35 -2.91 58.01 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.38 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.654 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.93 -17.3 7.35 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 120.652 0.263 . . . . 0.0 111.413 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.567 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.52 141.83 49.88 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.866 0.365 . . . . 0.0 111.213 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.5 mttt -89.05 131.68 35.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.797 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 114.42 -165.09 12.03 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.554 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -96.85 133.93 40.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.856 0.36 . . . . 0.0 110.872 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.468 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 57.1 m95 -130.4 167.49 18.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.595 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.0 t -135.42 155.94 49.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.019 0.438 . . . . 0.0 111.052 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -116.08 126.18 6.97 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.184 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 3.9 t -128.98 132.45 67.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.707 0.289 . . . . 0.0 111.269 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -84.61 111.63 19.71 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.824 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.566 HD22 ' CD1' ' A' ' 250' ' ' LEU . 38.2 mt -67.61 149.78 49.63 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.041 0.448 . . . . 0.0 111.498 -178.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -73.69 -26.52 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.212 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -136.8 170.67 10.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.405 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 19.9 Cg_exo -64.73 68.77 0.25 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.691 2.261 . . . . 0.0 112.082 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.566 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.61 27.86 6.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.211 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.803 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -108.67 -163.64 20.64 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.49 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 33.8 mmtt -123.79 -40.03 2.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.69 0.281 . . . . 0.0 111.202 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -116.93 169.77 9.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.909 0.385 . . . . 0.0 111.143 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -97.41 25.71 5.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.074 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 103.53 17.14 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.874 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.07 159.08 42.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.654 HG11 ' CD1' ' A' ' 236' ' ' PHE . 39.3 t -146.72 126.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.25 26.89 12.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.275 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 88.59 9.06 69.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.712 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 39.8 m -117.27 117.79 30.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.801 0.334 . . . . 0.0 110.832 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 16.8 ttp-105 -87.21 118.25 26.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.809 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -90.8 -31.12 16.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.503 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 9.1 p90 -157.78 172.28 18.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.643 179.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 14.9 tp60 -104.74 127.85 52.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.931 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 9.5 p -154.29 160.28 41.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.081 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.419 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 9.6 mm-40 -60.83 165.51 5.82 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.767 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.5 134.29 40.81 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.337 2.025 . . . . 0.0 112.077 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 5.4 mttt 64.01 18.73 11.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.251 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.426 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.1 m-85 -109.09 -16.64 14.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.052 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -81.86 118.48 4.63 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.733 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.6 tp -126.69 125.86 42.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.841 0.353 . . . . 0.0 110.431 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.503 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.1 m-85 -105.03 112.81 26.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.423 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.875 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.38 148.63 51.61 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.859 0.361 . . . . 0.0 111.07 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.754 ' O ' HG23 ' A' ' 278' ' ' VAL . 77.4 Cg_exo -49.39 162.74 0.49 Allowed 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 123.026 2.484 . . . . 0.0 112.798 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 11.5 p -69.87 -35.63 65.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.865 179.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.556 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.1 p-80 -74.89 -26.17 59.46 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.826 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.425 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.3 OUTLIER -77.8 -20.08 53.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.929 179.493 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.3 t -92.45 137.79 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.917 0.389 . . . . 0.0 111.05 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.55 132.22 46.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.894 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.0 130.6 44.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.713 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.451 HD12 HD21 ' A' ' 219' ' ' LEU . 20.1 tt -88.73 -29.41 5.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.083 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -67.9 118.39 9.62 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.426 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 4.9 p90 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.621 0.248 . . . . 0.0 110.965 179.936 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.436 0 N-CA-C 112.579 -0.208 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -131.12 55.18 1.86 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.799 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -171.64 -41.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -125.58 162.44 24.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.845 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 102.19 -9.4 56.22 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.746 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.515 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.9 mm-40 -95.45 30.89 2.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.667 0.234 . . . . 0.0 111.041 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.3 OUTLIER -140.16 153.09 46.53 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.958 0.409 . . . . 0.0 111.289 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.528 ' O ' HD12 ' A' ' 271' ' ' LEU . 46.5 m-85 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.298 -0.858 . . . . 0.0 110.92 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.841 0.353 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.15 -58.72 3.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.792 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.678 HD22 HG11 ' A' ' 218' ' ' VAL . 44.3 mt -122.38 149.49 43.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.56 144.91 41.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.843 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 34.5 mt -65.24 141.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.081 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 87.12 -2.53 86.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.698 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -94.15 147.7 22.9 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.846 0.355 . . . . 0.0 111.086 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.531 ' HD3' HG22 ' A' ' 227' ' ' VAL . 10.5 tpp85 -76.62 134.32 39.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.581 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.692 HG21 HG11 ' A' ' 278' ' ' VAL . 9.3 m -153.18 -175.88 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.063 0.459 . . . . 0.0 111.476 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.791 HD21 HD12 ' A' ' 281' ' ' ILE . 43.2 mt -124.58 121.58 35.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.161 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.2 111.86 22.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.956 0.408 . . . . 0.0 110.142 179.491 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.6 -6.35 82.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.472 -179.223 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.73 -26.72 10.08 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.715 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 33.0 p -99.48 -27.41 13.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.777 0.322 . . . . 0.0 110.882 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.441 ' HD3' HD12 ' A' ' 250' ' ' LEU . 1.6 mmpt? -99.74 147.64 25.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.757 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -120.4 145.17 47.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.021 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.408 ' HA3' HG12 ' A' ' 244' ' ' VAL . . . -176.1 -167.93 35.61 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.79 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.531 HG22 ' HD3' ' A' ' 217' ' ' ARG . 79.7 t -118.58 131.9 70.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.874 0.369 . . . . 0.0 110.96 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . 0.433 HG13 ' SG ' ' A' ' 242' ' ' CYS . 21.7 t -60.84 133.59 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.656 179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -121.0 -41.56 2.54 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.462 -179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -149.6 150.29 31.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.977 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 1.3 mp -133.96 119.85 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.821 0.343 . . . . 0.0 110.862 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 173.94 -172.5 45.34 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.445 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -79.73 159.26 26.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.357 . . . . 0.0 110.951 -179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.671 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 44.7 p -106.64 162.61 13.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.831 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -85.49 -4.61 59.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.408 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.682 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.0 p90 -124.05 -17.03 6.36 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.73 -0.214 . . . . 0.0 111.536 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.671 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.55 143.51 48.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.786 0.326 . . . . 0.0 111.281 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.01 156.38 19.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.805 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 89.0 -161.04 30.21 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.534 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . 0.404 ' OE1' HG21 ' A' ' 275' ' ' VAL . 10.9 pt-20 -102.68 137.94 40.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.895 0.378 . . . . 0.0 110.959 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.535 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 48.4 m95 -131.56 169.04 16.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.433 ' SG ' HG13 ' A' ' 228' ' ' VAL . 41.6 t -135.61 155.55 50.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.982 0.42 . . . . 0.0 111.133 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -114.6 126.33 7.21 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.148 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.408 HG12 ' HA3' ' A' ' 226' ' ' GLY . 4.8 t -129.37 132.69 66.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.402 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 32.7 tt0 -84.46 111.09 19.16 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.049 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.603 HD22 ' CD1' ' A' ' 250' ' ' LEU . 64.8 mt -67.67 145.17 55.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.067 0.461 . . . . 0.0 111.451 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.89 -23.38 59.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.142 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.436 ' CB ' ' HD2' ' A' ' 249' ' ' PRO . 0.4 OUTLIER -138.09 169.62 12.42 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.775 -179.963 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.473 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.0 Cg_endo -66.05 69.03 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.41 2.074 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.603 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.5 28.4 5.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.024 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.771 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -111.84 -174.06 19.6 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -116.31 -27.46 6.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.657 0.265 . . . . 0.0 111.443 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -124.29 168.69 12.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.849 0.357 . . . . 0.0 111.254 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -101.94 25.69 8.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.33 11.82 30.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.968 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -137.32 156.6 48.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.797 0.332 . . . . 0.0 111.112 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.682 HG11 ' CD1' ' A' ' 236' ' ' PHE . 59.3 t -141.46 122.17 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.048 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 57.92 26.08 12.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.247 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.72 10.86 61.19 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.66 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 6.6 m -117.36 115.16 24.69 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.827 0.346 . . . . 0.0 110.814 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -87.72 114.26 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.692 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -87.13 -32.88 19.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.2 p90 -155.95 177.0 11.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.824 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 -104.82 127.0 52.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.034 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 31.9 p -154.24 156.82 37.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.401 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 7.0 mt-30 -60.85 165.79 5.47 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.973 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.73 132.78 38.97 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.599 2.199 . . . . 0.0 112.149 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 34.6 mmtt 60.48 23.74 13.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.29 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.473 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -112.14 -19.21 12.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.054 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -80.35 127.53 7.98 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.811 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.3 tp -131.47 128.95 40.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 5.0 m-85 -107.77 112.73 25.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.355 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.897 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -142.18 147.94 46.03 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-O 120.972 0.415 . . . . 0.0 110.945 179.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.721 ' O ' HG23 ' A' ' 278' ' ' VAL . 76.1 Cg_exo -47.92 162.87 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.988 2.459 . . . . 0.0 112.664 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . 0.404 HG21 ' OE1' ' A' ' 240' ' ' GLU . 0.1 OUTLIER -68.12 -43.92 84.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.296 179.586 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.0 OUTLIER -68.23 -25.27 65.12 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.12 -179.475 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.462 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.1 OUTLIER -77.9 -20.46 52.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.778 0.323 . . . . 0.0 110.865 179.477 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 274' ' ' PRO . 21.4 t -93.93 138.92 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.086 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -130.66 136.06 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.015 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 135.82 57.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.791 HD12 HD21 ' A' ' 219' ' ' LEU . 11.5 tt -94.79 -29.71 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.012 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -156.46 141.38 7.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.622 0.249 . . . . 0.0 110.964 -179.926 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.549 -0.22 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -133.57 112.92 11.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.772 0.32 . . . . 0.0 110.959 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.81 175.72 9.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -137.89 162.71 33.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.7 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 66.28 25.75 72.46 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.475 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 1.7 mm-40 -94.51 27.06 3.13 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.482 0.182 . . . . 0.0 111.273 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.1 pt-20 -137.14 154.26 50.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.022 0.439 . . . . 0.0 111.258 -179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.604 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.3 m-85 . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.034 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.762 0.315 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -64.93 -31.82 73.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.933 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 46.2 mt -121.83 149.68 42.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.27 143.14 37.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.781 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . . . . . . . . . 38.7 mt -64.53 148.74 11.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.929 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 81.45 -0.72 87.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.72 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -94.12 146.63 23.84 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.912 0.387 . . . . 0.0 111.059 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.55 ' HD3' HG22 ' A' ' 227' ' ' VAL . 0.0 OUTLIER -76.69 134.77 39.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.684 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.705 HG21 HG11 ' A' ' 278' ' ' VAL . 8.6 m -153.35 -175.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.1 0.476 . . . . 0.0 111.469 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.724 HD21 HD12 ' A' ' 281' ' ' ILE . 43.0 mt -124.08 121.39 35.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.298 178.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.9 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.34 112.53 23.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.004 0.431 . . . . 0.0 110.121 179.38 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.58 -6.54 82.19 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.461 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 89.79 -25.26 11.95 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.735 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.4 p -100.23 -28.81 12.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.843 0.354 . . . . 0.0 110.975 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . . . . . . . . . 1.7 mmpt? -99.79 147.33 25.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.714 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 219' ' ' LEU . . . -118.37 144.45 45.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.257 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.405 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -173.36 -165.33 30.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.687 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.55 HG22 ' HD3' ' A' ' 217' ' ' ARG . 76.8 t -122.76 132.49 71.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.855 0.359 . . . . 0.0 110.954 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 21.9 t -60.2 131.63 25.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.552 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -121.17 -45.11 2.36 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.413 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -146.19 134.75 22.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.829 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.475 HD23 ' SG ' ' A' ' 242' ' ' CYS . 1.4 mp -120.27 130.01 54.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.798 0.332 . . . . 0.0 111.134 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 165.86 -176.28 41.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.507 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.71 161.72 25.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 31.1 p -107.96 169.91 8.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 33.9 t0 -96.76 0.08 48.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.413 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.603 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -124.09 -17.74 6.12 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 111.498 0.184 . . . . 0.0 111.498 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.432 ' HB1' ' CZ2' ' A' ' 241' ' ' TRP . . . -121.1 146.06 47.14 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.831 0.348 . . . . 0.0 111.188 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 6.9 ttpp -90.42 136.62 32.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.829 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 108.3 -172.23 16.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.487 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -90.7 137.65 32.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.768 0.318 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.432 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 55.8 m95 -132.82 168.67 17.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.972 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.475 ' SG ' HD23 ' A' ' 231' ' ' LEU . 42.8 t -137.79 155.88 48.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.071 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.439 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.16 126.15 7.06 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.16 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.467 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.5 t -129.09 132.57 67.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.405 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 37.4 tt0 -84.34 111.46 19.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.891 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.464 HD13 HD12 ' A' ' 250' ' ' LEU . 53.9 mt -67.54 147.66 52.49 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.088 0.471 . . . . 0.0 111.534 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -70.25 -27.5 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.088 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -136.13 170.22 11.54 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.872 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -65.81 70.0 0.37 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.57 2.18 . . . . 0.0 112.085 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.464 HD12 HD13 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.51 24.01 6.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.308 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.8 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -104.8 -164.58 24.18 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.531 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 35.8 mmtt -119.11 -37.98 3.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.715 0.293 . . . . 0.0 111.191 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.92 170.85 9.7 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.134 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -97.37 25.67 5.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 104.79 20.9 9.51 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.831 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 261' ' ' ARG . . . -138.14 159.05 43.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.814 0.34 . . . . 0.0 111.311 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.603 HG11 ' CD1' ' A' ' 236' ' ' PHE . 56.8 t -145.62 120.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.143 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 58.27 26.89 14.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.333 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 91.83 9.4 62.59 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.724 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 19.1 m -117.29 115.74 25.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.854 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 256' ' ' ALA . 1.4 ttt-85 -88.84 114.87 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.962 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -87.15 -32.24 19.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.753 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.504 ' CE1' ' CZ ' ' A' ' 272' ' ' PHE . 9.6 p90 -155.06 167.86 28.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.626 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.86 129.58 53.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 25.1 p -154.37 164.54 38.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.016 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.424 ' O ' ' HB2' ' A' ' 269' ' ' TYR . 5.6 mt-30 -60.92 165.71 5.67 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.792 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.85 133.71 43.1 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.359 2.039 . . . . 0.0 111.941 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt 62.67 18.66 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.337 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.424 ' HB2' ' O ' ' A' ' 266' ' ' GLN . 3.1 m-85 -109.15 5.83 24.29 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.173 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -104.07 118.34 5.95 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.752 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.2 tp -127.7 125.9 40.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.78 0.324 . . . . 0.0 110.574 179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.504 ' CZ ' ' CE1' ' A' ' 263' ' ' PHE . 5.0 m-85 -105.03 112.62 25.82 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.253 -179.456 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.88 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.79 148.56 53.18 Favored Pre-proline 0 C--O 1.232 0.153 0 CA-C-O 120.879 0.371 . . . . 0.0 111.095 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.76 ' O ' HG23 ' A' ' 278' ' ' VAL . 74.1 Cg_exo -47.72 162.38 0.25 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.017 2.478 . . . . 0.0 112.74 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 10.3 p -70.93 -35.3 59.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.77 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.534 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 1.2 p-80 -74.75 -25.77 59.32 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.455 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 2.3 mmpp? -77.96 -20.05 53.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.817 179.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.76 HG23 ' O ' ' A' ' 274' ' ' PRO . 17.5 t -94.49 140.48 16.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.022 0.439 . . . . 0.0 111.219 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.38 137.6 44.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.776 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.95 130.66 46.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.825 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . 0.724 HD12 HD21 ' A' ' 219' ' ' LEU . 11.8 tt -96.8 -30.9 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.113 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -93.02 73.81 1.3 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.555 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.235 0 CA-C-O 120.669 0.271 . . . . 0.0 110.895 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.186 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -88.67 -75.5 0.43 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.881 0.372 . . . . 0.0 110.826 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -74.4 -35.74 63.47 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -98.04 162.59 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.788 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 112.85 2.7 25.29 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.752 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.49 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.0 mt-10 -97.51 29.31 3.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.669 0.234 . . . . 0.0 110.948 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.9 OUTLIER -138.73 152.44 47.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 111.34 -179.692 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.584 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.4 m-85 . . . . . 0 C--O 1.248 0.989 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.757 0.313 . . . . 0.0 110.964 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -154.24 138.76 16.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.907 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . . . . . . . . . 66.5 mt -107.31 142.15 37.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.855 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.76 146.64 50.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.669 HG23 ' HA ' ' A' ' 229' ' ' ARG . 5.5 mt -58.13 143.24 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.985 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 86.59 -2.7 87.36 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.715 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.05 142.65 27.15 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.827 0.346 . . . . 0.0 110.977 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.599 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.0 tpp180 -76.75 134.52 39.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.452 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.672 HG21 HG11 ' A' ' 278' ' ' VAL . 10.4 m -153.74 -175.75 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.416 -179.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.458 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 37.0 mt -123.97 121.42 35.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.291 178.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.87 ' HB ' HD23 ' A' ' 271' ' ' LEU . 0.0 OUTLIER -88.97 111.71 23.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.858 0.361 . . . . 0.0 110.146 179.505 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 86.59 -6.51 82.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.497 -179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.1 -25.73 11.57 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.759 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 35.2 p -100.0 -28.21 13.18 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.844 0.354 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.486 ' HG3' HD21 ' A' ' 271' ' ' LEU . 0.6 OUTLIER -99.87 147.1 25.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.658 -179.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.458 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -119.79 142.79 48.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . . . . . . . . . . . -172.48 -165.12 29.07 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.73 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.599 HG22 ' HD3' ' A' ' 217' ' ' ARG . 75.5 t -122.47 133.96 67.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.694 0.283 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 26.3 t -61.03 131.87 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.559 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.669 ' HA ' HG23 ' A' ' 214' ' ' ILE . 2.5 mmm180 -120.65 -36.16 3.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.468 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -155.72 149.99 25.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.704 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.604 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.6 OUTLIER -133.53 131.44 39.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.887 0.375 . . . . 0.0 110.991 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.99 -174.01 40.08 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.355 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -79.89 162.75 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.796 0.332 . . . . 0.0 110.821 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.664 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.9 p -111.42 160.59 16.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -85.48 -4.63 59.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.463 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.644 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.2 p90 -121.15 -16.92 7.88 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 120.619 0.247 . . . . 0.0 111.384 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.664 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.17 138.04 53.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.839 0.352 . . . . 0.0 111.212 -179.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.05 132.88 34.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 111.3 -162.2 12.54 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.16 140.03 34.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.821 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.481 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 43.1 m95 -136.33 168.86 18.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.604 ' SG ' HD23 ' A' ' 231' ' ' LEU . 38.6 t -134.46 156.2 49.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.983 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.453 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.05 125.46 6.76 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.263 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . 0.447 ' CG2' HG13 ' A' ' 220' ' ' VAL . 4.1 t -129.16 131.52 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.787 0.327 . . . . 0.0 111.083 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -84.44 111.32 19.37 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.975 179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.511 HD22 ' CD1' ' A' ' 250' ' ' LEU . 56.7 mt -67.43 143.51 56.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.062 0.458 . . . . 0.0 111.511 -178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -68.89 -22.76 64.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.188 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.406 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -137.72 167.19 21.38 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.874 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.451 ' N ' ' CE1' ' A' ' 269' ' ' TYR . 37.6 Cg_endo -66.25 69.55 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.529 2.153 . . . . 0.0 112.204 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.511 ' CD1' HD22 ' A' ' 246' ' ' LEU . 0.3 OUTLIER -126.55 24.14 6.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.118 179.998 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.759 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -105.51 -179.54 23.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.479 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -112.57 -27.29 8.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.671 0.272 . . . . 0.0 111.164 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.3 p30 -118.41 160.27 21.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.904 0.383 . . . . 0.0 111.145 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -98.52 25.54 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.033 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 106.21 -0.99 37.79 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.883 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -127.9 158.63 37.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.644 HG11 ' CD1' ' A' ' 236' ' ' PHE . 61.8 t -141.05 118.44 8.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.978 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 60.18 25.44 14.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 93.49 10.84 58.87 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.78 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 29.6 m -117.19 116.53 27.46 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.853 0.358 . . . . 0.0 110.844 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 37.8 ttm180 -89.1 114.16 25.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -88.86 -33.28 17.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.805 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.498 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 8.3 p90 -155.85 173.82 16.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.676 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 7.6 tp60 -104.84 129.66 53.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 10.3 p -154.28 161.34 41.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.032 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . 0.4 ' HG3' ' HD2' ' A' ' 267' ' ' PRO . 4.2 mp0 -60.83 165.76 5.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.815 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . 0.4 ' HD2' ' HG3' ' A' ' 266' ' ' GLN . 34.7 Cg_endo -65.03 128.09 19.9 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.006 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 14.2 mmtt 65.37 24.88 12.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.075 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.451 ' CE1' ' N ' ' A' ' 249' ' ' PRO . 2.9 m-85 -111.55 -19.24 12.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.101 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -77.48 132.34 11.94 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.877 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.87 HD23 ' HB ' ' A' ' 220' ' ' VAL . 11.0 tp -137.93 125.75 22.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.438 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.498 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.7 m-85 -105.11 112.85 26.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.464 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.861 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -140.58 149.3 56.62 Favored Pre-proline 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.037 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.716 ' O ' HG23 ' A' ' 278' ' ' VAL . 60.2 Cg_exo -50.37 163.16 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.942 2.428 . . . . 0.0 112.621 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.77 -45.6 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.411 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.545 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.22 -25.1 66.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.092 -179.582 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 0.0 OUTLIER -78.92 -20.35 49.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.793 0.33 . . . . 0.0 110.901 179.522 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 274' ' ' PRO . 25.4 t -95.0 139.29 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.189 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.26 141.39 46.97 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.88 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -70.53 131.52 44.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.767 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 4.0 tt -83.19 -28.52 7.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.143 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 98.71 -112.99 4.6 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.375 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 . . . . . 0 C--N 1.329 -0.326 0 CA-C-O 120.681 0.277 . . . . 0.0 110.869 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.542 -0.223 . . . . 0.0 112.542 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.36 106.97 12.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.904 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.92 74.26 1.05 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.755 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 -141.22 162.61 35.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.889 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 74.42 20.7 79.53 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.706 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 2.6 mt-10 -106.13 23.15 14.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.542 0.171 . . . . 0.0 111.038 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 0.5 OUTLIER -137.35 155.36 49.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.931 0.396 . . . . 0.0 111.335 -179.7 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.649 ' O ' HD12 ' A' ' 271' ' ' LEU . 45.9 m-85 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.01 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.848 0.356 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -153.55 162.94 40.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 212' ' ' LEU . . . . . 0.462 HD22 HG11 ' A' ' 218' ' ' VAL . 88.8 mt -112.57 147.56 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.934 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 213' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.96 148.5 52.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 214' ' ' ILE . . . . . 0.737 HG23 ' HA ' ' A' ' 229' ' ' ARG . 4.1 mt -59.38 138.92 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.891 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 215' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.5 79.25 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.691 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 216' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.81 141.43 28.51 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.824 0.345 . . . . 0.0 111.064 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 217' ' ' ARG . . . . . 0.63 ' HD3' HG22 ' A' ' 227' ' ' VAL . 5.6 tpp180 -76.76 130.52 37.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.543 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 218' ' ' VAL . . . . . 0.721 HG21 HG11 ' A' ' 278' ' ' VAL . 12.7 m -149.99 -176.4 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.598 -179.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.466 ' CD2' ' HB2' ' A' ' 225' ' ' ALA . 32.1 mt -124.1 121.45 35.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.239 179.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 220' ' ' VAL . . . . . 0.89 HG12 ' HB3' ' A' ' 273' ' ' ALA . 0.0 OUTLIER -89.84 111.36 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.027 0.441 . . . . 0.0 110.083 179.56 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 221' ' ' GLY . . . . . . . . . . . . . . . 87.33 -6.45 83.35 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.543 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' GLY . . . . . . . . . . . . . . . 90.32 -25.54 12.44 Favored Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.698 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' THR . . . . . . . . . . . . . 21.1 p -101.4 -26.97 13.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.921 0.391 . . . . 0.0 110.917 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' LYS . . . . . 0.572 ' HE2' HD13 ' A' ' 250' ' ' LEU . 0.8 OUTLIER -99.78 147.02 25.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.522 -179.936 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.466 ' HB2' ' CD2' ' A' ' 219' ' ' LEU . . . -121.38 145.24 48.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' GLY . . . . . 0.404 ' CA ' ' O ' ' A' ' 245' ' ' GLU . . . -175.99 -166.88 34.06 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.529 -0.843 . . . . 0.0 112.901 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' VAL . . . . . 0.63 HG22 ' HD3' ' A' ' 217' ' ' ARG . 74.1 t -119.79 133.59 66.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.737 0.303 . . . . 0.0 111.04 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' VAL . . . . . . . . . . . . . 34.8 t -61.35 129.62 24.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.601 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' ARG . . . . . 0.737 ' HA ' HG23 ' A' ' 214' ' ' ILE . 6.2 mmt180 -118.77 -32.62 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.738 -179.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -157.18 148.45 21.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.681 0.277 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.542 HD23 ' SG ' ' A' ' 242' ' ' CYS . 0.8 OUTLIER -133.9 119.83 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.804 0.335 . . . . 0.0 111.008 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 174.23 -172.58 45.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.456 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -79.85 162.4 25.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.815 0.341 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.608 ' OG1' ' HB3' ' A' ' 237' ' ' ALA . 29.7 p -111.27 163.94 13.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -88.38 -4.41 58.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.427 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' PHE . . . . . 0.611 ' CD1' HG11 ' A' ' 257' ' ' VAL . 2.1 p90 -122.12 -16.85 7.37 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.702 -0.227 . . . . 0.0 111.491 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' ALA . . . . . 0.608 ' HB3' ' OG1' ' A' ' 234' ' ' THR . . . -120.32 139.16 53.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.937 0.399 . . . . 0.0 111.241 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 7.4 ptmt -86.14 132.91 33.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.835 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . 110.99 -166.26 12.27 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.618 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -96.63 137.11 36.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' TRP . . . . . 0.5 ' CZ2' ' HB1' ' A' ' 237' ' ' ALA . 44.4 m95 -133.56 169.15 17.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' CYS . . . . . 0.542 ' SG ' HD23 ' A' ' 231' ' ' LEU . 43.3 t -134.04 155.98 49.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.059 0.457 . . . . 0.0 110.98 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' GLY . . . . . 0.452 ' HA3' ' CE1' ' A' ' 263' ' ' PHE . . . -115.36 126.72 7.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.115 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.13 132.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.832 0.348 . . . . 0.0 111.097 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' GLU . . . . . 0.404 ' O ' ' CA ' ' A' ' 226' ' ' GLY . 29.4 tt0 -84.4 111.54 19.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.954 179.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' LEU . . . . . 0.436 HD12 ' CA ' ' A' ' 251' ' ' GLY . 95.2 mt -67.51 141.61 56.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.061 0.458 . . . . 0.0 111.381 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -68.75 -27.39 65.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.99 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' GLU . . . . . 0.429 ' CB ' HD23 ' A' ' 250' ' ' LEU . 0.5 OUTLIER -133.9 168.13 19.4 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.644 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' A' ' 248' ' ' GLU . 37.8 Cg_endo -66.33 68.74 0.46 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.439 2.093 . . . . 0.0 112.217 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' LEU . . . . . 0.572 HD13 ' HE2' ' A' ' 224' ' ' LYS . 0.2 OUTLIER -126.42 27.11 6.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.098 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 271' ' ' LEU . . . -110.31 -159.94 17.47 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.433 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' LYS . . . . . . . . . . . . . 10.3 mmtt -125.81 -38.09 2.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -118.76 167.55 11.58 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.946 0.403 . . . . 0.0 111.009 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -98.15 25.71 5.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.092 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 105.26 19.69 10.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.728 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' ALA . . . . . . . . . . . . . . . -138.02 158.99 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.861 0.362 . . . . 0.0 111.181 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.611 HG11 ' CD1' ' A' ' 236' ' ' PHE . 54.3 t -144.32 121.49 5.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.089 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' ALA . . . . . . . . . . . . . . . 56.85 25.01 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.423 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' GLY . . . . . . . . . . . . . . . 97.08 -5.89 63.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.82 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' THR . . . . . . . . . . . . . 41.0 m -102.35 117.29 34.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.901 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -89.84 119.86 30.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.817 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -92.96 -35.66 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.734 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' PHE . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 272' ' ' PHE . 6.3 p90 -151.25 166.98 29.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' GLN . . . . . . . . . . . . . 17.4 tp60 -104.8 130.13 52.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.885 0.374 . . . . 0.0 111.129 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' CYS . . . . . . . . . . . . . 12.1 p -154.46 165.21 37.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' GLN . . . . . . . . . . . . . 8.1 mt-30 -60.74 165.16 6.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.821 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -61.37 129.4 28.12 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.427 2.085 . . . . 0.0 111.895 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER 63.48 20.42 12.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.256 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' TYR . . . . . 0.407 ' CD2' ' O ' ' A' ' 246' ' ' LEU . 3.3 m-85 -111.46 21.17 16.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.963 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' GLY . . . . . . . . . . . . . . . -124.21 127.1 6.34 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.499 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' LEU . . . . . 0.874 HD23 ' HB ' ' A' ' 220' ' ' VAL . 10.5 tp -132.86 133.37 43.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.824 0.345 . . . . 0.0 110.722 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' PHE . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 263' ' ' PHE . 4.8 m-85 -108.07 112.53 25.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.055 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' ALA . . . . . 0.89 ' HB3' HG12 ' A' ' 220' ' ' VAL . . . -141.03 150.04 57.82 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.893 0.378 . . . . 0.0 111.143 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' PRO . . . . . 0.726 ' O ' HG23 ' A' ' 278' ' ' VAL . 66.8 Cg_exo -49.2 162.84 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.989 2.46 . . . . 0.0 112.558 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -68.46 -45.39 82.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.46 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' HIS . . . . . 0.525 ' CD2' ' HB2' ' A' ' 274' ' ' PRO . 0.9 OUTLIER -66.08 -25.54 67.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.198 -179.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' LYS . . . . . 0.454 ' HD2' ' HB2' ' B' ' 449' ' ' GLU . 3.8 mmtp -78.29 -20.54 51.33 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.101 179.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 274' ' ' PRO . 19.7 t -94.41 137.62 22.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.04 0.448 . . . . 0.0 111.003 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.64 141.21 50.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.001 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.99 129.33 39.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.78 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' ILE . . . . . . . . . . . . . 7.3 tt -77.97 -27.48 14.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.104 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 99.38 26.68 8.56 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.59 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.628 0.251 . . . . 0.0 110.919 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 444' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 445' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.13 -62.46 0.06 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 446' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -101.01 28.77 5.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 447' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -141.22 162.66 34.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 448' ' ' GLY . . . . . . . . . . . . . . . 70.28 18.12 74.77 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.783 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 449' ' ' GLU . . . . . 0.479 ' O ' ' HD3' ' A' ' 274' ' ' PRO . 0.8 OUTLIER -99.63 26.0 6.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.559 0.218 . . . . 0.0 110.902 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 450' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 272' ' ' PHE . 1.4 pt-20 -140.81 155.05 46.46 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.9 0.381 . . . . 0.0 111.304 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 451' ' ' TYR . . . . . 0.619 ' O ' HD12 ' A' ' 271' ' ' LEU . 42.9 m-85 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.991 -179.964 . . . . . . . . 1 1 . 1 stop_ save_